Dr Lisa Horvath

Conduit C; Inderjeeth AJ; Allen R; Martin AJ; Parulekar W; Mulroe E; McJannett M; Zielinski RR; Thomson A; Tan TH; Sandhu SK; Reaume MN; Pook DW; North SA; Marx GM; Joshua A; Horvath L; McDermott R; Chowdhury S; Chi KN; Zhang AY; Stockler MR; Davis ID; Sweeney CJ, 2025, 'Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)', Future oncology (London, England), 21, pp. 627 - 636, http://dx.doi.org/10.1080/14796694.2024.2440277

Crumbaker M; Krieger L; Pook DW; Davis ID; Fontela A; Oldmeadow C; Hurwitz J; Inderjeeth AJ; Dhillon HM; Downton T; Marx GM; Shekar S; Antonarakis ES; Denmeade SR; Anton A; Tan TH; Sharma S; Goh JC; Horvath L; Joshua AM, 2025, 'Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.tps298

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Sandhu S; Nguyen A; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Kumar ASR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; McJannett M; Thomas H; Langford A; Hofman MS; Martin AJ; Davis ID; Stockler MR; Subramaniam S; Joshua AM; Sandhu S; Nguyen A; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Gedye C; Rutherford NK; Ravi Kumar AS; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Butler P; Zhang AY; Thomas H; Langford A; Hofman MS; Martin AJ; Stockler MR; Zebic D; Mak B; Tankard N; Rana N; Cusick T; Thompson J; Oakes S; Niu C; Thein T; Ford K; Ristevski N; Yip S; Bills M, 2025, 'Overall survival and quality of life with [¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial', The Lancet Oncology, 26, pp. 291 - 299, http://dx.doi.org/10.1016/S1470-2045(25)00009-9

Scheinberg T; Kench JG; Ferguson P; Sutherland S; Stockler MR; Mahon KL; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Marx GM; Davis ID; Sengupta S; Leslie S; Centenera MM; Butler L; Horvath L, 2025, 'LEEP: A randomised, window of opportunity, neoadjuvant trial examining the pharmacodynamic effects of ribociclib prior to radical prostatectomy for high-risk, localised prostate cancer.', Journal of Clinical Oncology, 43, pp. 392 - 392, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.392

Tie J; Wang Y; Lo SN; Lahouel K; Cohen JD; Wong R; Shapiro JD; Harris SJ; Khattak A; Burge ME; Lee M; Harris M; McLachlan SA; Horvath L; Karapetis C; Shannon J; Singh M; Yip D; Ananda S; Underhill C; Ptak J; Silliman N; Dobbyn L; Popoli M; Papadopoulos N; Tomasetti C; Kinzler KW; Vogelstein B; Gibbs P, 2025, 'Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial', Nature Medicine, http://dx.doi.org/10.1038/s41591-025-03579-w

Armstrong AJ; Appleman LJ; Danila DC; Lin C-C; Lee JL; Matsubara N; Ward PJ; Pook DW; Kim M; Dorff TB; Fischer SC; Lin Y-C; Horvath LG; Sumey C; Yang Z; Decato BE; Englert JM; Smith KM; Lolkema M; Kelly WK, 2024, '1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig', Annals of Oncology, 35, pp. S971 - S972, http://dx.doi.org/10.1016/j.annonc.2024.08.1691

Azad A; Gurney H; Underhill C; Horvath L; Voskoboynik M; Li X; King I; Shao L; Dai Y; Perabo F, 2024, 'Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 42, pp. 124 - 124, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.124

Azad A; UNDERHILL CR; Gurney H; Horvath L; Voskoboynik M; Ellerington S; Dai Y; King I; Perabo F; Guo G, 2024, 'Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 42, pp. 5058 - 5058, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5058

Azad A; Voskoboynik M; Joshua AM; Weickhardt AJ; Sankey P; Pacey S; Heath EI; Krieger L; Horvath L; Pilie PG; Womersley L; Linardopoulos S; Moorthy G; Zhou TJ; Brown J; de Paula B; Lukacs E; Hudson A, 2024, 'PETRANHA: Phase 1/2 study of AZD5305+novel hormonal agents in patients with metastatic prostate cancer-Interim safety and pharmacokinetic results.', JOURNAL OF CLINICAL ONCOLOGY, 42, pp. 123 - 123, http://dx.doi.org/10.1200/JCO.2024.42.4_suppl.123

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [¹⁷⁷Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', The Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

Brown KGM; Morkaya J; Solomon MJ; Ng KS; White K; Sutton P; Steffens D; Winter DC; Ansari N; Austin K; Brown W; Butow P; Byrne C; Carey S; Dumitrescu A; Hatcher S; Horvath L; Koh C; Lee P; Mahon K; Mcbride K; Salkeld G; Sandroussi C; Yeo D, 2024, 'Priority outcomes of pelvic exenteration for rectal cancer: a patient, carer, and clinician consensus', British Journal of Surgery, 111, http://dx.doi.org/10.1093/bjs/znae298

Connolly EA; Bucio-Noble D; Cai S; Singh A; Koh J; Karim R; Lazar A; Lim R; Morey R; Ratnayake G; Hains P; Ye L; Ingram D; Scott CL; Robinson PJ; Barker H; Nassif Haddad EF; Horvath LG; Grimison P; Reddel R, 2024, '1727MO Can proteomics predict metastatic relapse in leiomyosarcoma (LMS)? Development of an 8 protein signature in a >350 sample study including a validation cohort', Annals of Oncology, 35, pp. S1034 - S1035, http://dx.doi.org/10.1016/j.annonc.2024.08.1819

Davis ID; Martin AJ; Zielinski RR; Thomson A; Tan TH; Sandhu S; Reaume MN; Pook DW; Parnis F; North SA; Marx GM; McCaffrey J; McDermott RS; Inderjeeth AJ; Horvath L; Frydenberg M; Chowdhury S; Chi KN; Stockler MR; Sweeney C, 2024, 'Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304).', Journal of Clinical Oncology, 42, pp. 151 - 151, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.151

Dorff T; Horvath LG; Autio K; Bernard-Tessier A; Rettig MB; Machiels JP; Bilen MA; Lolkema MP; Adra N; Rottey S; Greil R; Matsubara N; Tan DSW; Wong A; Uemura H; Lemech C; Meran J; Yu Y; Minocha M; McComb M; Penny HL; Gupta V; Hu X; Jurida G; Kouros-Mehr H; Janat-Amsbury MM; Eggert T; Tran B, 2024, 'A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer', Clinical Cancer Research, 30, pp. 1488 - 1500, http://dx.doi.org/10.1158/1078-0432.CCR-23-2978

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID, 2024, '[¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial', The Lancet Oncology, 25, pp. 563 - 571, http://dx.doi.org/10.1016/S1470-2045(24)00135-9

Fethney J; Kim B; Boustany C; McKenzie H; Hayes L; Cox K; Simpson JM; Horvath LG; Vardy JL; McLeod J; Willcock S; Cook N; Acret L; White K, 2024, 'Correction to: Evaluating a shared care pathway intervention for people receiving chemotherapy to reduce post‑treatment unplanned hospital presentations: a randomised controlled trial (Supportive Care in Cancer, (2024), 32, 1, (77), 10.1007/s00520-023-08261-w)', Supportive Care in Cancer, 32, http://dx.doi.org/10.1007/s00520-024-08326-4

Fethney J; Kim B; Boustany C; McKenzie H; Hayes L; Cox K; Simpson JM; Horvath LG; Vardy JL; McLeod J; Willcock S; Cook N; Acret L; White K, 2024, 'Evaluating a shared care pathway intervention for people receiving chemotherapy to reduce post-treatment unplanned hospital presentations: a randomised controlled trial', Supportive Care in Cancer, 32, http://dx.doi.org/10.1007/s00520-023-08261-w

Finney J; Felmingham B; Kumar S; Mahmood A; Horvath L; Celermajer D; Conyers R, 2024, 'Abstract PO2-20-06: Using the Australian Cardio-Oncology Registry to study long-term cancer therapy related cardiac dysfunction in adult oncology patients – The Chris O’Brien Lifehouse experience', Cancer Research, 84, http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-20-06

Hamid AA; Thomas H; Martin A; Soon YY; Horvath LG; Zielinski R; Thomson A; Tan H; Sandhu SK; Reaume MN; Pook DW; Parnis F; McDermott RS; Lawrence N; Frydenberg M; Chi KN; Stockler MR; Davis ID; Sweeney C, 2024, '1618P Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)', Annals of Oncology, 35, pp. S977 - S978, http://dx.doi.org/10.1016/j.annonc.2024.08.1699

Horvath LG; Lin H-M; Davis ID; Martin A; Scheinberg T; Meikle P; Joshua A; Mcjannett M; Subhash V; Yip S; North S; McDermott RS; Chi KN; Stockler MR; Sweeney C, 2024, '1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)', Annals of Oncology, 35, pp. S969 - S970, http://dx.doi.org/10.1016/j.annonc.2024.08.1688

Kelly WK; Appleman LJ; Lin C-C; Armstrong AJ; Fischer SC; Pook DW; Perez Gracia JL; Lee JL; Berthold DR; Ward PJ; Castellano Gauna DE; Horvath LG; Kim M; Matsubara N; Sumey C; Shabooti M; Yang Z; Connarn J; Stieglmaier J; Danila DC, 2024, '1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study', Annals of Oncology, 35, pp. S963 - S964, http://dx.doi.org/10.1016/j.annonc.2024.08.1679

Kelly WK; Danila DC; Lin CC; Lee JL; Matsubara N; Ward PJ; Armstrong AJ; Pook D; Kim M; Dorff TB; Fischer S; Lin YC; Horvath LG; Sumey C; Yang Z; Jurida G; Smith KM; Connarn JN; Penny HL; Stieglmaier J; Appleman LJ, 2024, 'Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic CastrationResistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study', Cancer Discovery, 14, pp. 76 - 89, http://dx.doi.org/10.1158/2159-8290.CD-23-0964

Li T; Timmins HC; Mahfouz FM; Mizrahi D; Horvath L; Harrison ML; Grimison PS; Friedlander M; Marx GM; Boyle FM; Wyld D; Henderson R; King T; Baron-Hay SE; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Identifying optimized assessment of nerve damage during chemotherapy.', Journal of Clinical Oncology, 42, pp. 12016 - 12016, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12016

Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy', JAMA Network Open, 7, pp. e2424139, http://dx.doi.org/10.1001/jamanetworkopen.2024.24139

Lin HM; Yang X; Centenera MM; Huynh K; Giles C; Dehairs J; Swinnen JV; Hoy AJ; Meikle PJ; Butler LM; Taplin ME; Horvath LG, 2024, 'Circulating Lipid Profiles Associated with Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.24.00260

Mahfouz FM; Li T; Joda M; Harrison M; Horvath LG; Grimison P; King T; Marx G; Goldstein D; Park SB, 2024, 'Sleep dysfunction associated with worse chemotherapy-induced peripheral neurotoxicity functional outcomes', Supportive Care in Cancer, 32, http://dx.doi.org/10.1007/s00520-023-08245-w

Mahfouz FM; Li T; Joda M; Harrison M; Kumar S; Horvath LG; Grimison P; King T; Goldstein D; Park SB, 2024, 'Upper-limb dysfunction in cancer survivors with chemotherapy-induced peripheral neurotoxicity', Journal of the Neurological Sciences, 457, http://dx.doi.org/10.1016/j.jns.2023.122862

Mahfouz FM; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Marx G; Goldstein D; Park SB, 2024, 'Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity', JNCCN Journal of the National Comprehensive Cancer Network, 22, pp. 108 - 116, http://dx.doi.org/10.6004/jnccn.2023.7083

Mahon KL; Sutherland SIM; Lin HM; Stockler MR; Gurney H; Mallesara G; Briscoe K; Marx G; Higano CS; de Bono JS; Chi KN; Clark G; Breit SN; Brown DA; Horvath LG, 2024, 'Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer', Prostate, 84, pp. 747 - 755, http://dx.doi.org/10.1002/pros.24691

Mc Laughlin RA; Thomas H; Davis ID; Zielinski RR; Thomson A; Tan TH; Sandhu S; Reaume MN; Pook DW; Parnis F; North SA; Marx GM; McCaffrey J; McDermott RS; Horvath L; Frydenberg M; Chowdhury S; Chi KN; Stockler MR; Sweeney C, 2024, 'Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).', Journal of Clinical Oncology, 42, pp. 5079 - 5079, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5079

Mellor R; Ardolino L; Scheinberg T; Fitzpatrick M; Lin HM; Bonnitcha P; Sullivan D; Meikle PJ; Stockler MR; Moujaber T; Joshua A; Horvath L, 2024, 'Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy', Therapeutic Advances in Medical Oncology, 16, http://dx.doi.org/10.1177/17588359241307814

Niazi T; Nguyen PL; Williams S; Stockler MR; Martin AJ; Horvath L; Thomas H; Zebic DS; Roncolato F; Lim T; Jose C; Martin J; Chung HT; Ebacher A; Morgan SC; Hughes S; McBride SM; Kelly PJ; Davis ID; Sweeney C, 2024, 'Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).', Journal of Clinical Oncology, 42, pp. 328 - 328, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.328

O Parsonson A; Grimison P; Boyer M; Horvath L; Mahon K; Beith J; Kao S; Hui M; Sutherland S; Kumar S; Heller G; McNeil C, 2024, 'Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemic', Journal of Telemedicine and Telecare, 30, pp. 320 - 326, http://dx.doi.org/10.1177/1357633X211045586

Parsonson A; Grimison P; Boyer M; Horvath L; Mahon K; Beith J; Kao S; Hui M; Sutherland S; Kumar S; Heller G; McNeil C, 2024, 'Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemic', JOURNAL OF TELEMEDICINE AND TELECARE, 30, pp. 320 - 326, http://dx.doi.org/10.1177/1357633X211045586

Pidsley R; Lam D; Qu W; Stricker P; Kench JG; Horvath LG; Clark SJ, 2024, 'Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer', BJUI Compass, 5, pp. 1299 - 1306, http://dx.doi.org/10.1002/bco2.445

Scheinberg T; Lin HM; Fitzpatrick M; Azad AA; Bonnitcha P; Davies A; Heller G; Huynh K; Mak B; Mahon K; Sullivan D; Meikle PJ; Horvath LG, 2024, 'PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer', Prostate Cancer and Prostatic Diseases, 27, pp. 136 - 143, http://dx.doi.org/10.1038/s41391-023-00666-2

Sharifi N; Diaz R; Lin HM; Roberts E; Horvath LG; Martin A; Stockler MR; Yip S; Subhash VV; Portman N; Davis ID; Sweeney CJ, 2024, 'Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance', Journal of Clinical Investigation, 134, http://dx.doi.org/10.1172/JCI183583

Strach MC; Yeung N; Apostolov E; Wang T; Lin H-M; Ansari N; Koh C; Shin J-S; Kench J; Swarbrick A; Horvath L; Mahon KL, 2024, 'Abstract 5480: Single cell and spatial transcriptomic profile of appendiceal tumour peritoneal disease', Cancer Research, 84, pp. 5480 - 5480, http://dx.doi.org/10.1158/1538-7445.am2024-5480

Teppala S; Scuffham P; Edmunds K; Roberts MJ; Fairbairn D; Smith DP; Horvath L; Tuffaha H, 2024, 'The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers', Value in Health, 27, pp. 1515 - 1527, http://dx.doi.org/10.1016/j.jval.2024.06.019

Tolmeijer SH; Kwan EM; Ng SWS; Joshua A; Emmett L; Crumbaker M; Hamid AA; Anton A; Horvath LG; Chan J; Bressel M; Buteau JP; Dhiantravan N; Ayati N; Keerthikumar S; Goode D; Hicks R; Hofman MS; Wyatt AW; Sandhu SK, 2024, '1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)', Annals of Oncology, 35, pp. S975 - S976, http://dx.doi.org/10.1016/j.annonc.2024.08.1697

Tuffaha H; Edmunds K; Fairbairn D; Roberts MJ; Chambers S; Smith DP; Horvath L; Arora S; Scuffham P, 2024, 'Guidelines for genetic testing in prostate cancer: a scoping review', Prostate Cancer and Prostatic Diseases, 27, pp. 594 - 603, http://dx.doi.org/10.1038/s41391-023-00676-0

Yeung N; Li T; Lin HM; Timmins HC; Goldstein D; Harrison M; Friedlander M; Mahon KL; Giles C; Meikle PJ; Park SB; Horvath LG, 2024, 'Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00690

Clark KC; Nguyen EV; Niranjan B; Wu Y; Lim Kam Sian TCC; Horvath LG; Taylor RA; Daly RJ, 2023, 'Cell-Type-Specific Signalling Networks Impacted by Prostate Epithelial-Stromal Intercellular Communication', Cancers, 15, http://dx.doi.org/10.3390/cancers15030699

Conduit C; Mak B; Qu W; Yeung T; Bressel M; Cusick T; Dhillon HM; De Abreu Lourenço R; Underhill C; Torres J; Crumbaker M; Honeyball F; Linton A; Sewak S; Chau NMH; Allen R; Davis ID; Clark SJ; Horvath L; Mahon KL, 2023, 'GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).', Journal of Clinical Oncology, 41, pp. TPS5099 - TPS5099, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps5099

Connolly EA; Grimison PS; Horvath LG; Robinson PJ; Reddel RR, 2023, 'Quantitative proteomic studies addressing unmet clinical needs in sarcoma', Frontiers in Oncology, 13, http://dx.doi.org/10.3389/fonc.2023.1126736

Day D; Starus A; Gebski V; Simes J; Hayes T; Padinharakam S; Strickland AH; Briscoe K; Varma S; Barnet M; Jackson C; Horvath LG; Price TJ; Tebbutt N; Karki B; Diakos CI; Chia J; Toh HC; Jones FS; Segelov E, 2023, 'Minimal residual disease (MRD) detection using a tumour naive circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial', ANNALS OF ONCOLOGY, 34, pp. S426 - S427, http://dx.doi.org/10.1016/j.annonc.2023.09.1777

Fang S; Zhe S; Lin HM; Azad AA; Fettke H; Kwan EM; Horvath L; Mak B; Zheng T; Du P; Jia S; Kirby RM; Kohli M, 2023, 'Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer', JCO Clinical Cancer Informatics, 7, http://dx.doi.org/10.1200/CCI.23.00057

Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LJK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA, 2023, 'BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype', eBioMedicine, 95, http://dx.doi.org/10.1016/j.ebiom.2023.104738

Fettke H; Dai C; Kwan EM; Zheng T; Tan W; Du P; Ng N; Bukszynska P; Docanto M; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA, 2023, 'Abstract 2303: Adverse clinical outcomes and distinct genomic phenotype of BRCA-deficient metastatic castration-resistant prostate cancer (mCRPC)', Cancer Research, 83, pp. 2303 - 2303, http://dx.doi.org/10.1158/1538-7445.am2023-2303

Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney C; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ngozi Ekeke O; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis CJ; Mahal BA; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Pablo Sade J; Sartor OA; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H, 2023, 'Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022', European Urology, 83, pp. 267 - 293, http://dx.doi.org/10.1016/j.eururo.2022.11.002

Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ekeke ON; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis C; Mahal B; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro CJ; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H, 2023, 'Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022', European Journal of Cancer, 185, pp. 178 - 215, http://dx.doi.org/10.1016/j.ejca.2023.02.018

Horvath L; Lin H-M; Huynh K; Meikle T; Joshua AM; Azad A; Tan W; Butler L; Meikle P, 2023, 'Circulating ether lipids in prostate cancer.', Journal of Clinical Oncology, 41, pp. e17009 - e17009, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e17009

Horvath LG; Davis ID; Martin A; Zielinski R; Thomson A; Tan TH; Sandhu SK; Reaume MN; Pook D; Parnis F; North S; Marx GM; McCaffrey JA; McDermott RS; Lawrence N; Frydenberg M; Chowdhury S; Chi KNN; Stockler MR; Sweeney C, 2023, 'Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)', ANNALS OF ONCOLOGY, 34, pp. S968 - S969, http://dx.doi.org/10.1016/j.annonc.2023.09.2742

Horvath LG; Kench C; Mellor R; Lin H-M; Mak B; Scheinberg T; Mahon K; Graham L; Azad AA; Joshua AM; Stockler MR; Marx GM; Briscoe K; Samaras K, 2023, 'Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?', ANNALS OF ONCOLOGY, 34, pp. S991 - S991, http://dx.doi.org/10.1016/j.annonc.2023.09.2779

Kelly W; Danila D; Lin C-C; Lee J-L; Matsubara N; Ward P; Armstrong AJ; Pook D; Kim M; Dorff T; Fischer S; Lin Y-C; Horvath LG; Sumey C; Yang Z; Jurida G; Connarn J; Penny H; Stieglmaier J; Appleman LJ, 2023, 'Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)', ANNALS OF ONCOLOGY, 34, pp. S953 - S954, http://dx.doi.org/10.1016/j.annonc.2023.09.2715

Kelly WK; Danila DC; Lin C-C; Lee J-L; Matsubara N; Ward PJ; Armstrong AJ; Pook DW; Kim M; Dorff T; Fischer S; Lin Y-C; Horvath LG; Sumey C; Yang Z; Jurida G; Connarn J; Penny H; Stieglmaier J; Appleman LJ, 2023, 'Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)', ANNALS OF ONCOLOGY, 34, pp. S1576 - S1576, http://dx.doi.org/10.1016/j.annonc.2023.10.390

Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB, 2023, 'Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes', JNCCN Journal of the National Comprehensive Cancer Network, 21, pp. 125 - 132, http://dx.doi.org/10.6004/jnccn.2022.7074

Scheinberg T; Mak B; Butler L; Selth L; Horvath LG, 2023, 'Targeting lipid metabolism in metastatic prostate cancer', Therapeutic Advances in Medical Oncology, 15, http://dx.doi.org/10.1177/17588359231152839

Strach MC; Yeung N; Lin H-M; Ansari N; Koh C; Shin J-S; Kench J; Horvath L; Mahon KL, 2023, 'Characteristics of immune-infiltrating cells in the tumor microenvironment of appendiceal cancer with peritoneal disease.85', JOURNAL OF CLINICAL ONCOLOGY, 41, pp. 217 - 217

Sutherland SIM; Ju X; Silveira PA; Kupresanin F; Horvath LG; Clark GJ, 2023, 'CD300f signalling induces inhibitory human monocytes/macrophages', Cellular Immunology, 390, http://dx.doi.org/10.1016/j.cellimm.2023.104731

Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Cheung L; Chi KN; Chowdhury S; Frydenberg M; Horvath LG; Joshua AM; Lawrence NJ; Marx G; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Vera-Badillo F; Williams SG; Winter D; Yip S; Zhang AY; Zielinski RR; Davis ID; Abdi E; Allan S; Bastick P; Blum R; Briscoe K; Brungs D; Bydder S; Chittajallu BR; Cronk M; Cuff K; Dowling A; George M; Hovey E; Karanth N; Kichenadasse G; Krieger L; Mathlum M; Nott L; Otty Z; Sewak S; Stevanovic A; Stockler M; Suder A; Tan H; Torres J; Troon S; Underhill C; Weickhardt A; Zielinski R; Abbas T; Anan G; Booth C; Campbell H; Chin J; Chouinard E; Donnelly B; Drachenberg D; Faghih A; Finelli A; Hotte S; Noonan K; Rassouli M; Reaume N; Rendon R; Saad F; Sadikov E; Vigneault E; Zalewski P; Morris P; O'Connor M; Donnellan P; O'Donnell D; Edwards J; Fong P; Crabb S; Khan O; Khoo V; Macdonald G; Payne H; Robinson A; Shamash J; Staffurth J; Thomas C, 2023, 'Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial', The Lancet Oncology, 24, pp. 323 - 334, http://dx.doi.org/10.1016/S1470-2045(23)00063-3

Wang A; Shen J; Rodriguez AA; Saunders EJ; Chen F; Janivara R; Darst BF; Sheng X; Xu Y; Chou AJ; Benlloch S; Dadaev T; Brook MN; Plym A; Sahimi A; Hoffman TJ; Takahashi A; Matsuda K; Momozawa Y; Fujita M; Laisk T; Figuerêdo J; Muir K; Ito S; Liu X; Yamanashi Y; Furukawa Y; Morisaki T; Murakami Y; Muto K; Nagai A; Obara W; Yamaji K; Takahashi K; Asai S; Takahashi Y; Suzuki T; Sinozaki N; Yamaguchi H; Minami S; Murayama S; Yoshimori K; Nagayama S; Obata D; Higashiyama M; Masumoto A; Koretsune Y; Uchio Y; Kubo M; Kamatani Y; Lophatananon A; Wan P; Andrews C; Lori A; Choudhury PP; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Giles GG; Southey MC; MacInnis RJ; Cybulski C; Wokolorczyk D; Lubinski J; Rentsch CT; Cho K; Mcmahon BH; Neal DE; Donovan JL; Hamdy FC; Martin RM; Nordestgaard BG; Nielsen SF; Weischer M; Bojesen SE; Røder A; Stroomberg HV; Batra J; Chambers S; Horvath L; Clements JA; Tilly W; Risbridger GP; Gronberg H; Aly M; Szulkin R; Eklund M; Nordstrom T; Pashayan N; Dunning AM; Ghoussaini M; Travis RC; Key TJ; Riboli E; Park JY; Sellers TA; Lin HY; Albanes D; Weinstein S, 2023, 'Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants', Nature Genetics, 55, pp. 2065 - 2074, http://dx.doi.org/10.1038/s41588-023-01534-4

Wu Y; Clark KC; Niranjan B; Chüeh AC; Horvath LG; Taylor RA; Daly RJ, 2023, 'Integrative characterisation of secreted factors involved in intercellular communication between prostate epithelial or cancer cells and fibroblasts', Molecular Oncology, 17, pp. 469 - 486, http://dx.doi.org/10.1002/1878-0261.13376

Yeung N; Lin H-M; Timmins H; Li T; Goldstein D; Friedlander M; Harrison ML; Mahon KL; Meikle P; Park S; Horvath L, 2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.', Journal of Clinical Oncology, 41, pp. 3031 - 3031, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3031

Centenera MM; Vincent AD; Moldovan M; Lin HM; Lynn DJ; Horvath LG; Butler LM, 2022, 'Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants', Cancers, 14, http://dx.doi.org/10.3390/cancers14071708

Chiong E; Murphy DG; Buchan NC; Chua MLK; Hakim L; Hamid AR; Hong SK; Horvath LG; Kanesvaran R; Khochikar M; Letran J; Lojanapiwat B; Malek R; Ng ACF; Vinh NT; Pang ST; Poon DMC; Ong TA; Saad M; Schubach K; Shiroki R; Türkeri L; Williams S; Wong A; Ye D; Davis ID, 2022, 'Managing advanced prostate cancer in the Asia Pacific region: “Real-world” application of Advanced Prostate Cancer Consensus Conference 2019 statements', Asia-Pacific Journal of Clinical Oncology, 18, pp. 686 - 695, http://dx.doi.org/10.1111/ajco.13722

Conduit C; Mak B; Qu W; Lulio JD; Burder R; Bressel M; Cusick T; Dhillon HM; Lourenço RDA; Underhill C; Torres J; Crumbaker M; Honeyball F; Linton A; Allen R; Davis ID; Clark SJ; Horvath LG; Mahon KL, 2022, 'GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)', Therapeutic Advances in Medical Oncology, 14, http://dx.doi.org/10.1177/17588359221092486

Fizazi K; González Mella P; Castellano D; Minatta JN; Rezazadeh Kalebasty A; Shaffer D; Vázquez Limón JC; Sánchez López HM; Armstrong AJ; Horvath L; Bastos DA; Amin NP; Li J; Unsal-Kacmaz K; Retz M; Saad F; Petrylak DP; Pachynski RK, 2022, 'Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial', European Journal of Cancer, 160, pp. 61 - 71, http://dx.doi.org/10.1016/j.ejca.2021.09.043

Horvath LG; Taylor RA; Daly RJ, 2022, 'Preface: Novel Therapeutic Targets and Biomarkers in Prostate Cancer', Critical Reviews in Oncogenesis, 27, pp. vii - ix, http://dx.doi.org/10.1615/CritRevOncog.2022043661

Jaratlerdsiri W; Jiang J; Gong T; Patrick SM; Willet C; Chew T; Lyons RJ; Haynes AM; Pasqualim G; Louw M; Kench JG; Campbell R; Horvath LG; Chan EKF; Wedge DC; Sadsad R; Brum IS; Mutambirwa SBA; Stricker PD; Bornman MSR; Hayes VM, 2022, 'African-specific molecular taxonomy of prostate cancer', Nature, 609, pp. 552 - 559, http://dx.doi.org/10.1038/s41586-022-05154-6

Mahfouz FM; Park SB; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; King T; Goldstein D; Mizrahi D, 2022, 'Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients', Clinical Autonomic Research, 32, pp. 497 - 506, http://dx.doi.org/10.1007/s10286-022-00895-w

Mak B; Lin HM; Duong T; Mahon KL; Joshua AM; Stockler MR; Gurney H; Parnis F; Zhang A; Scheinberg T; Wittert G; Butler LM; Sullivan D; Hoy AJ; Meikle PJ; Horvath LG, 2022, 'Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin', Cancers, 14, http://dx.doi.org/10.3390/cancers14194792

Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG, 2022, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', BMC Medicine, 20, http://dx.doi.org/10.1186/s12916-022-02298-0

Pidsley R; Lam D; Qu W; Peters TJ; Phuc-Loi L; Korbie D; Stirzaker C; Daly RJ; Stricker P; Kench JG; Horvath LG; Clark SJ, 2022, 'Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality', CLINICAL AND TRANSLATIONAL MEDICINE, 12, http://dx.doi.org/10.1002/ctm2.1030

Scheinberg T; Fitzpatrick M; Lin H-M; Azad AA; Bonnitcha P; Davies AG; Heller G; Huynh K; Mak B; Mahon K; Meikle P; Sullivan D; Horvath LG, 2022, '1409P Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention', Annals of Oncology, 33, pp. S1189 - S1189, http://dx.doi.org/10.1016/j.annonc.2022.07.1895

Smith MR; Scher HI; Sandhu S; Efstathiou E; Lara PN; Yu EY; George DJ; Chi KN; Saad F; Ståhl O; Olmos D; Danila DC; Mason GE; Espina BM; Zhao X; Urtishak KA; Francis P; Lopez-Gitlitz A; Fizazi K; Parnis F; Joshua AM; Horvath LG; Steer C; Marx G; Gurney H; Ferguson T; Van Bruwaene S; Luyten D; Schatteman P; Lumen N; Dirix L; Goeminne JC; Gil T; Seront E; Vulsteke C; Kussumoto C; Franke FA; Martinelli de Oliveira FA; Pereira de Santana Gomes AJ; Pinczowski H; Preto DDA; Zucca LE; Borges GS; Murad AM; Fradet Y; Fleshner NE; Emmenegger U; Brasso K; Culine S; Thiery-Vuillemin A; Joly F; Fléchon A; Hilgers W; Eymard JC; Borchiellini D; Barthélémy P; Berger R; Leibowitz-Amit R; Mermershtain W; Rouvinov K; Peer A; Kovel S; Sella A; Lolkema MP; van den Eertwegh AJM; Voortman J; Aarts MJ; Gietema JA; Kim CS; Choi YD; Chung BH; Gafanov RA; Kopyltsov E; Usynin EA; Carles J; Mellado B; Maroto JP; García-Donás J; Rodríguez Moreno JF; Durán I; Pérez-Valderrama B; Castro E; Méndez-Vidal MJ; Estellés DL; Sarrió RG; Muñoz-Langa J; Herranz UA; Puente Vázquez J; Castellanos E; Hellström M; Widmark A; Lissbrant IF; Jellvert Å; Külich C; Blom R; Chiang PH; Kang CH; Ou YC; Wang SS; Wu HC, 2022, 'Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial', The Lancet Oncology, 23, pp. 362 - 373, http://dx.doi.org/10.1016/S1470-2045(21)00757-9

Stockler MR; Martin AJ; Davis ID; Dhillon HM; Begbie SD; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx GM; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar WR; Pook DW; Reaume MN; Sandhu S; Tan A; Tan TH; Thomson A; Vera-Badillo F; Williams SG; Winter DG; Yip S; Zhang AY; Zielinski RR; Sweeney CJ, 2022, 'Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP', Journal of Clinical Oncology, 40, pp. 837 - 846, http://dx.doi.org/10.1200/JCO.21.00941

Strach MC; Sutherland S; Horvath LG; Mahon K, 2022, 'The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions', Therapeutic Advances in Medical Oncology, 14, http://dx.doi.org/10.1177/17588359221112478

Timmins HC; Li T; Goldstein D; Trinh T; Mizrahi D; Harrison M; Horvath LG; Friedlander M; Kiernan MC; Park SB, 2022, 'The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors', Journal of Cancer Survivorship, 16, pp. 223 - 232, http://dx.doi.org/10.1007/s11764-021-01012-y

Toro C; Felmingham B; Jessop S; Celermajer DS; Kotecha RS; Govender D; Terese Hanna DM; O'Connor M; Manudhane R; Ayer J; O'Sullivan J; Sullivan M; Costello B; La Gerche A; Walwyn T; Horvath L; Mateos MK; Fulbright J; Jadhav M; Cheung M; Eisenstat D; Elliott DA; Conyers R, 2022, 'Cardio-Oncology Recommendations for Pediatric Oncology Patients: An Australian and New Zealand Delphi Consensus', JACC: Advances, 1, http://dx.doi.org/10.1016/j.jacadv.2022.100155

Wu Y; Clark KC; Nguyen EV; Niranjan B; Horvath LG; Taylor RA; Daly RJ, 2022, 'Proteomic characterisation of prostate cancer intercellular communication reveals cell type-selective signalling and TMSB4X-dependent fibroblast reprogramming', Cellular Oncology, 45, pp. 1311 - 1328, http://dx.doi.org/10.1007/s13402-022-00719-z

Strach MC; Yeung N; Apostolov E; Lin H-M; Nagaraju RT; Ansari N; Koh C; Shin J-S; Kench J; Aziz O; Swarbrick A; Horvath LG; Barriuso J; Mahon K, 2022, 'Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease', ANNALS OF ONCOLOGY, vol. 33, pp. S1322 - S1322, http://dx.doi.org/10.1016/j.annonc.2022.07.1791

Tie J; Cohen J; Lahouel K; Lo SN; Wang Y; Wong R; Shapiro J; Harris S; Khattak A; Burge M; Horvath LG; Karapetis CS; Shannon J; Singh M; Yip D; Papadopoulos N; Tomasetti C; Kinzler K; Vogelstein B; Gibbs P, 2022, 'Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)', ANNALS OF ONCOLOGY, vol. 33, pp. S683 - S683, http://dx.doi.org/10.1016/j.annonc.2022.07.456

Butler LM; Mah CY; Machiels J; Vincent AD; Irani S; Mutuku SM; Spotbeen X; Bagadi M; Waltregny D; Moldovan M; Dehairs J; Vanderhoydonc F; Bloch K; Das R; Stahl J; Kench JG; Gevaert T; Derua R; Waelkens E; Nassar ZD; Selth LA; Trim PJ; Snel MF; Lynn DJ; Tilley WD; Horvath LG; Centenera MM; Swinnen JV, 2021, 'Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition', Cancer Research, 81, pp. 4981 - 4993, http://dx.doi.org/10.1158/0008-5472.CAN-20-3863

Conti DV; Darst BF; Moss LC; Saunders EJ; Sheng X; Chou A; Schumacher FR; Olama AAA; Benlloch S; Dadaev T; Brook MN; Sahimi A; Hoffmann TJ; Takahashi A; Matsuda K; Momozawa Y; Fujita M; Muir K; Lophatananon A; Wan P; Le Marchand L; Wilkens LR; Stevens VL; Gapstur SM; Carter BD; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Giles GG; Southey MC; MacInnis RJ; Cybulski C; Wokołorczyk D; Lubiński J; Neal DE; Donovan JL; Hamdy FC; Martin RM; Nordestgaard BG; Nielsen SF; Weischer M; Bojesen SE; Røder MA; Iversen P; Batra J; Chambers S; Moya L; Horvath L; Clements JA; Tilley W; Risbridger GP; Gronberg H; Aly M; Szulkin R; Eklund M; Nordström T; Pashayan N; Dunning AM; Ghoussaini M; Travis RC; Key TJ; Riboli E; Park JY; Sellers TA; Lin HY; Albanes D; Weinstein SJ; Mucci LA; Giovannucci E; Lindstrom S; Kraft P; Hunter DJ; Penney KL; Turman C; Tangen CM; Goodman PJ; Thompson IM; Hamilton RJ; Fleshner NE; Finelli A; Parent MÉ; Stanford JL; Ostrander EA; Geybels MS; Koutros S; Freeman LEB; Stampfer M; Wolk A; Håkansson N; Andriole GL; Hoover RN; Machiela MJ; Sørensen KD; Borre M; Blot WJ; Zheng W; Yeboah ED; Mensah JE; Lu YJ, 2021, 'Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (Nature Genetics, (2021), 53, 1, (65-75), 10.1038/s41588-020-00748-0)', Nature Genetics, 53, pp. 413, http://dx.doi.org/10.1038/s41588-021-00786-2

Conti DV; Darst BF; Moss LC; Saunders EJ; Sheng X; Chou A; Schumacher FR; Olama AAA; Benlloch S; Dadaev T; Brook MN; Sahimi A; Hoffmann TJ; Takahashi A; Matsuda K; Momozawa Y; Fujita M; Muir K; Lophatananon A; Wan P; Le Marchand L; Wilkens LR; Stevens VL; Gapstur SM; Carter BD; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Giles GG; Southey MC; MacInnis RJ; Cybulski C; Wokołorczyk D; Lubiński J; Neal DE; Donovan JL; Hamdy FC; Martin RM; Nordestgaard BG; Nielsen SF; Weischer M; Bojesen SE; Røder MA; Iversen P; Batra J; Chambers S; Moya L; Horvath L; Clements JA; Tilley W; Risbridger GP; Gronberg H; Aly M; Szulkin R; Eklund M; Nordström T; Pashayan N; Dunning AM; Ghoussaini M; Travis RC; Key TJ; Riboli E; Park JY; Sellers TA; Lin HY; Albanes D; Weinstein SJ; Mucci LA; Giovannucci E; Lindstrom S; Kraft P; Hunter DJ; Penney KL; Turman C; Tangen CM; Goodman PJ; Thompson IM; Hamilton RJ; Fleshner NE; Finelli A; Parent MÉ; Stanford JL; Ostrander EA; Geybels MS; Koutros S; Freeman LEB; Stampfer M; Wolk A; Håkansson N; Andriole GL; Hoover RN; Machiela MJ; Sørensen KD; Borre M; Blot WJ; Zheng W; Yeboah ED; Mensah JE; Lu YJ, 2021, 'Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction', Nature Genetics, 53, pp. 65 - 75, http://dx.doi.org/10.1038/s41588-020-00748-0

Kwan EM; Dai C; Fettke H; Hauser C; Docanto MM; Bukczynska P; Ng N; Foroughi S; Graham LJK; Mahon K; Tan W; Wang X; Zhao Z; Zheng T; Zhou K; Yu J; Du P; Horvath LG; Jia S; Kohli M; Azad AA, 2021, 'Plasma cell-free dna profiling of pten-pi3kakt pathway aberrations in metastatic castration-resistant prostate cancer', JCO Precision Oncology, 5, pp. 622 - 637, http://dx.doi.org/10.1200/PO.20.00424

Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LJK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA, 2021, 'Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer', Translational Andrology and Urology, 10, http://dx.doi.org/10.21037/tau-20-1444

Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LJK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA, 2021, 'Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer', European Urology Focus, 7, pp. 63 - 70, http://dx.doi.org/10.1016/j.euf.2019.04.020

Lin HM; Huynh K; Kohli M; Tan W; Azad AA; Yeung N; Mahon KL; Mak B; Sutherland PD; Shepherd A; Mellett N; Docanto M; Giles C; Centenera MM; Butler LM; Meikle PJ; Horvath LG, 2021, 'Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer', Prostate Cancer and Prostatic Diseases, 24, pp. 860 - 870, http://dx.doi.org/10.1038/s41391-021-00338-z

Lin HM; Mak B; Yeung N; Huynh K; Meikle TG; Mellett NA; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Crumbaker M; Stricker PD; Du P; Yu J; Jia S; Scheinberg T; Fitzpatrick M; Bonnitcha P; Sullivan DR; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG, 2021, 'Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase', EBioMedicine, 72, http://dx.doi.org/10.1016/j.ebiom.2021.103625

Lin HM; Yeung N; Hastings JF; Croucher DR; Huynh K; Meikle TG; Mellett NA; Kwan EM; Davis ID; Tran B; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Bastick P; Crumbaker ML; Joshua AM; Azad AA; Meikle PJ; Horvath LG, 2021, 'Relationship between circulating lipids and cytokines in metastatic castration‐resistant prostate cancer', Cancers, 13, http://dx.doi.org/10.3390/cancers13194964

Murphy KJ; Reed DA; Vennin C; Conway JRW; Nobis M; Yin JX; Chambers CR; Pereira BA; Lee V; Filipe EC; Trpceski M; Ritchie S; Lucas MC; Warren SC; Skhinas JN; Magenau A; Metcalf XL; Stoehr J; Major G; Parkin A; Bidanel R; Lyons RJ; Zaratzian A; Tayao M; Da Silva A; Abdulkhalek L; Gill AJ; Johns AL; Biankin AV; Samra J; Grimmond SM; Chou A; Goetz JG; Samuel MS; Lyons JG; Burgess A; Caldon CE; Horvath LG; Daly RJ; Gadegaard N; Wang Y; Sansom OJ; Morton JP; Cox TR; Pajic M; Herrmann D; Timpson P, 2021, 'Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status', Science Advances, 7, http://dx.doi.org/10.1126/sciadv.abh0363

Sarkar S; Tran B; Horvath L; Lam M; Savas P; Grimison P; Whittle JR; Kuo JC; Signal N; Edmonds D; Hogg P; Rischin D; Desai J; Hamilton A, 2021, 'A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours', Cancer Chemotherapy and Pharmacology, 87, pp. 613 - 620, http://dx.doi.org/10.1007/s00280-020-04225-7

Scheinberg T; Goodwin A; Ip E; Linton A; Mak B; Smith DP; Stockler MR; Strach MC; Tran B; Young AL; Zhang AY; Mahon KL; Horvath LG, 2021, 'Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer', JCO oncology practice, 17, pp. e204 - e216, http://dx.doi.org/10.1200/OP.20.00399

Scheinberg T; Young A; Woo H; Goodwin A; Mahon KL; Horvath LG, 2021, 'Mainstream consent programs for genetic counseling in cancer patients: A systematic review', Asia-Pacific Journal of Clinical Oncology, 17, pp. 163 - 177, http://dx.doi.org/10.1111/ajco.13334

Sutherland SIM; Ju X; Horvath LG; Clark GJ, 2021, 'Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer', Frontiers in Immunology, 12, http://dx.doi.org/10.3389/fimmu.2021.641307

Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx GM; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Davis ID, 2021, 'Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy', European Urology, 80, pp. 275 - 279, http://dx.doi.org/10.1016/j.eururo.2021.05.016

Wang Q; Guan YF; Hancock SE; Wahi K; van Geldermalsen M; Zhang BK; Pang A; Nagarajah R; Mak B; Freidman N; Horvath LG; Turner N; Holst J, 2021, 'Inhibition of guanosine monophosphate synthetase (GMPS) blocks glutamine metabolism and prostate cancer growth', Journal of Pathology, 254, pp. 135 - 146, http://dx.doi.org/10.1002/path.5665

Wu SZ; Roden DL; Al-Eryani G; Bartonicek N; Harvey K; Cazet AS; Chan CL; Junankar S; Hui MN; Millar EA; Beretov J; Horvath L; Joshua AM; Stricker P; Wilmott JS; Quek C; Long GV; Scolyer RA; Yeung BZ; Segara D; Mak C; Warrier S; Powell JE; O’Toole S; Lim E; Swarbrick A, 2021, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', Genome Medicine, 13, http://dx.doi.org/10.1186/s13073-021-00885-z

Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M, 2020, 'Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors', Journal for ImmunoTherapy of Cancer, 8, http://dx.doi.org/10.1136/jitc-2019-000453

Desai J; Gan H; Barrow C; Jameson M; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Parente P; Tran B; Wang L; Chen Y; Tang Z; Huang W; Wu J; Zeng D; Luo L; Solomon B, 2020, 'Phase I, open-label, dose-escalation/ dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors', Journal of Clinical Oncology, 38, pp. 2140 - 2150, http://dx.doi.org/10.1200/JCO.19.02654

Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LJK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA, 2020, 'Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer', European Urology, 78, pp. 173 - 180, http://dx.doi.org/10.1016/j.eururo.2020.03.044

Hollis B; Day FR; Busch AS; Thompson DJ; Soares ALG; Timmers PRHJ; Kwong A; Easton DF; Joshi PK; Timpson NJ; Eeles RA; Henderson BE; Haiman CA; Kote-Jarai Z; Schumacher FR; Olama AAA; Benlloch S; Muir K; Berndt SI; Conti DV; Wiklund F; Chanock S; Gapstur S; Stevens VL; Tangen CM; Batra J; Clements J; Gronberg H; Pashayan N; Schleutker J; Albanes D; Wolk A; West C; Mucci L; Cancel-Tassin G; Koutros S; Sorensen KD; Grindedal EM; Neal DE; Hamdy FC; Donovan JL; Travis RC; Hamilton RJ; Ingles SA; Rosenstein BS; Lu YJ; Giles GG; Kibel AS; Vega A; Kogevinas M; Penney KL; Park JY; Stanford JL; Cybulski C; Nordestgaard BG; Brenner H; Maier C; Kim J; John EM; Teixeira MR; Neuhausen SL; De Ruyck K; Razack A; Newcomb LF; Lessel D; Kaneva R; Usmani N; Claessens F; Townsend PA; Gago-Dominguez M; Roobol MJ; Menegaux F; Khaw KT; Cannon-Albright L; Pandha H; Thibodeau SN; Agee M; Alipanahi B; Auton A; Bell RK; Bryc K; Elson SL; Fontanillas P; Furlotte NA; Hinds DA; Huber KE; Kleinman A; Litterman NK; McIntyre MH; Mountain JL; Noblin ES; Northover CAM; Pitts SJ; Sathirapongsasuti JF; Sazonova OV; Shelton JF; Shringarpure S; Tian C; Tung JY; Vacic V, 2020, 'Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan', Nature Communications, 11, http://dx.doi.org/10.1038/s41467-020-14451-5

Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA, 2020, 'Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer', EBioMedicine, 54, http://dx.doi.org/10.1016/j.ebiom.2020.102728

Li T; Timmins HC; McCrary JM; Trinh T; Horvath LG; Friedlander ML; Kiernan MC; Goldstein D; Park SB, 2020, '5. Neurophysiological characteristics in the development and recovery of peripheral neuropathy in oxaliplatin and paxlitaxel treated patients', Clinical Neurophysiology, 131, pp. e2 - e3, http://dx.doi.org/10.1016/j.clinph.2019.11.038

Miladinovic D; Cusick T; Mahon KL; Haynes AM; Cortie CH; Meyer BJ; Stricker PD; Wittert GA; Butler LM; Horvath LG; Hoy AJ, 2020, 'Assessment of periprostatic and subcutaneous adipose tissue lipolysis and adipocyte size from men with localized prostate cancer', Cancers, 12, http://dx.doi.org/10.3390/cancers12061385

Nassar ZD; Mah CY; Dehairs J; Burvenich IJG; Irani S; Centenera MM; Helm M; Shrestha RK; Moldovan M; Don AS; Holst J; Scott AM; Horvath LG; Lynn DJ; Selth LA; Hoy AJ; Swinnen JV; Butler LM, 2020, 'Human decr1 is an androgen-repressed survival factor that regulates pufa oxidation to protect prostate tumor cells from ferroptosis', eLife, 9, pp. 1 - 34, http://dx.doi.org/10.7554/eLife.54166

Niazi T; Williams S; Davis ID; Stockler MR; Martin AJ; Hague W; Bracken K; Gorzeman M; Roncolato F; Yip S; Horvath L; Sengupta S; Hughes S; McDermott RS; Catto JWF; Vapiwala N; Parulekar WR; Sweeney C, 2020, 'DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.', Journal of Clinical Oncology, 38, pp. TPS385 - TPS385, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.tps385

Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth D; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A, 2020, '1530P Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis', Annals of Oncology, 31, pp. S942 - S942, http://dx.doi.org/10.1016/j.annonc.2020.08.2013

Scheinberg T; Goodwin A; Ip E; Linton A; Mak B; Smith DP; Stockler MR; Strach MC; Tran B; Young AL; Zhang AY; Mahon KL; Horvath L, 2020, 'Evaluation of a mainstream model of genetic testing for men with prostate cancer.', Journal of Clinical Oncology, 38, pp. 1521 - 1521, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1521

Scheinberg T; Kench J; Stockler M; Mahon KL; Sebastian L; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Centenera MM; Butler LM; Horvath LG, 2020, 'Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)', BMJ Open, 10, http://dx.doi.org/10.1136/bmjopen-2019-033667

Schwarzenbacher E; Moik F; Posch F; Horvath L; Gantschnigg A; Renneberg F; Barth D; Stotz M; Schaberl-Moser R; Pichler M; Ay C; Stöger H; Greil R; Djanani A; Gerger A; Schlick K; Riedl JM, 2020, '1552P Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX', Annals of Oncology, 31, pp. S949 - S950, http://dx.doi.org/10.1016/j.annonc.2020.08.2035

Timmins HC; Li T; Kiernan MC; Horvath LG; Goldstein D; Park SB, 2020, 'Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients', Journal of Pain, 21, pp. 44 - 58, http://dx.doi.org/10.1016/j.jpain.2019.06.011

Tran B; Horvath L; Dorff TB; Greil R; Machiels J-PH; Roncolato F; Autio KA; Rettig M; Fizazi K; Lolkema MP; Fermin AC; Salvati M; Kouros-Mehr H, 2020, 'Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 38, pp. TPS261 - TPS261, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.tps261

Voskoboynik M; Richardson GE; Mileshkin LR; McNeil CM; Horvath L; Benedetti FM; Choy GS; Sankar N; McCurry S; Zhang X; Gao M; Shah AK; Millward M, 2020, 'A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.', Journal of Clinical Oncology, 38, pp. e15125 - e15125, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e15125

Wang Q; Guan Y; Hancock S; Wahi K; van Geldermalsen M; Zhang B; Pang A; Nagarajah R; Mak B; Horvath L; Turner N; Holst J, 2020, 'Inhibition of guanosine monophosphate synthetase (GMPS) blocks glutamine metabolism and prostate cancer growthin vitroandin vivo', , http://dx.doi.org/10.1101/2020.09.07.286997

Wu S; Roden D; Al-Eryani G; Bartonicek N; Harvey K; Cazet A; Chan C-L; Junankar S; Hui M; Millar E; Beretov J; Horvath L; Joshua A; Stricker P; Wilmott J; Quek C; Long G; Scolyer R; Yeung B; Segara D; Mak C; Warrier S; Powell J; O'Toole S; Lim E; Swarbrick A, 2020, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', bioRxiv, http://dx.doi.org/10.1101/2020.06.04.135277

Balaban S; Nassar ZD; Zhang AY; Hosseini-Beheshti E; Centenera MM; Schreuder M; Lin HM; Aishah A; Varney B; Liu-Fu F; Lee LS; Nagarajan SR; Shearer RF; Hardie RA; Raftopulos NL; Kakani MS; Saunders DN; Holst J; Horvath LG; Butler LM; Hoy AJ, 2019, 'Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer', Molecular Cancer Research, 17, pp. 949 - 962, http://dx.doi.org/10.1158/1541-7786.MCR-18-0347

Castillo L; George S; Lin H-M; Yeung N; Mawson A; Young AI; Law AM; Hastings J; Gallego-Ortega D; Deng N; Croucher D; Swarbrick A; Horvath L; Ormandy CJ; Oakes SR, 2019, 'Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p038

Crumbaker M; Emmett L; Horvath LG; Joshua AM, 2019, 'Exceptional response to ¹⁷⁷lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237

Davis ID; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx G; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Neil Reaume M; Sandhu SK; Tan A; Hsiang Tan T; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Sweeney CJ, 2019, 'Enzalutamide with standard first-line therapy in metastatic prostate cancer', New England Journal of Medicine, 381, pp. 121 - 131, http://dx.doi.org/10.1056/NEJMoa1903835

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM, 2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial ⁶⁸Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099

Gamell C; Bandilovska I; Gulati T; Kogan A; Lim SC; Kovacevic Z; Takano EA; Timpone C; Agupitan AD; Litchfield C; Blandino G; Horvath LG; Fox SB; Williams SG; Russo A; Gallo E; Paul PJ; Mitchell C; Sandhu S; Keam SP; Haupt S; Richardson DR; Haupt Y, 2019, 'E6AP Promotes a Metastatic Phenotype in Prostate Cancer', iScience, 22, pp. 1 - 15, http://dx.doi.org/10.1016/j.isci.2019.10.065

Gillessen S; Horvath LG, 2019, 'Statins – No more cream for cancer', European Journal of Cancer, 112, pp. 107 - 108, http://dx.doi.org/10.1016/j.ejca.2019.02.008

Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ, 2019, 'Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target', Neoplasia (United States), 21, pp. 389 - 400, http://dx.doi.org/10.1016/j.neo.2019.02.005

Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG, 2019, 'Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial', European Urology, 76, pp. 306 - 312, http://dx.doi.org/10.1016/j.eururo.2018.11.001

Matejcic M; Saunders EJ; Dadaev T; Brook MN; Wang K; Sheng X; Olama AAA; Schumacher FR; Ingles SA; Govindasami K; Benlloch S; Berndt SI; Albanes D; Koutros S; Muir K; Stevens VL; Gapstur SM; Tangen CM; Batra J; Clements J; Gronberg H; Pashayan N; Schleutker J; Wolk A; West C; Mucci L; Kraft P; Cancel-Tassin G; Sorensen KD; Maehle L; Grindedal EM; Strom SS; Neal DE; Hamdy FC; Donovan JL; Travis RC; Hamilton RJ; Rosenstein B; Lu YJ; Giles GG; Kibel AS; Vega A; Bensen JT; Kogevinas M; Penney KL; Park JY; Stanford JL; Cybulski C; Nordestgaard BG; Brenner H; Maier C; Kim J; Teixeira MR; Neuhausen SL; De Ruyck K; Razack A; Newcomb LF; Lessel D; Kaneva R; Usmani N; Claessens F; Townsend PA; Gago-Dominguez M; Roobol MJ; Menegaux F; Khaw KT; Cannon-Albright LA; Pandha H; Thibodeau SN; Schaid DJ; Henderson BE; Stern MC; Thwaites A; Guy M; Whitmore I; Morgan A; Fisher C; Hazel S; Livni N; Cook M; Fachal L; Weinstein S; Beane Freeman LE; Hoover RN; Machiela MJ; Lophatananon A; Carter BD; Goodman P; Moya L; Srinivasan S; Kedda MA; Yeadon T; Eckert A; Eklund M; Cavalli-Bjoerkman C; Dunning AM; Sipeky C; Hakansson N; Elliott R; Ranu H, 2019, 'Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1)', Nature Communications, 10, http://dx.doi.org/10.1038/s41467-019-08293-z

McCrary JM; Goldstein D; Sandler CX; Barry BK; Marthick M; Timmins HC; Li T; Horvath L; Grimison P; Park SB, 2019, 'Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy', Supportive Care in Cancer, 27, pp. 3849 - 3857, http://dx.doi.org/10.1007/s00520-019-04680-w

Quinn DI; Stricker PD; Kench JG; Grogan J; Haynes AM; Henshall SM; Grygiel JJ; Delprado W; Turner JJ; Horvath LG; Mahon KL, 2019, 'p53 nuclear accumulation as an early indicator of lethal prostate cancer', British Journal of Cancer, 121, pp. 578 - 583, http://dx.doi.org/10.1038/s41416-019-0549-8

Schumacher FR; Olama AAA; Berndt SI; Benlloch S; Ahmed M; Saunders EJ; Dadaev T; Leongamornlert D; Anokian E; Cieza-Borrella C; Goh C; Brook MN; Sheng X; Fachal L; Dennis J; Tyrer J; Muir K; Lophatananon A; Stevens VL; Gapstur SM; Carter BD; Tangen CM; Goodman PJ; Thompson IM; Batra J; Chambers S; Moya L; Clements J; Horvath L; Tilley W; Risbridger GP; Gronberg H; Aly M; Nordström T; Pharoah P; Pashayan N; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Albanes D; Weinstein S; Wolk A; Håkansson N; West CML; Dunning AM; Burnet N; Mucci LA; Giovannucci E; Andriole GL; Cussenot O; Cancel-Tassin G; Koutros S; Beane Freeman LE; Sorensen KD; Orntoft TF; Borre M; Maehle L; Grindedal EM; Neal DE; Donovan JL; Hamdy FC; Martin RM; Travis RC; Key TJ; Hamilton RJ; Fleshner NE; Finelli A; Ingles SA; Stern MC; Rosenstein BS; Kerns SL; Ostrer H; Lu YJ; Zhang HW; Feng N; Mao X; Guo X; Wang G; Sun Z; Giles GG; Southey MC; MacInnis RJ; FitzGerald LM; Kibel AS; Drake BF; Vega A; Gómez-Caamaño A; Szulkin R; Eklund M; Kogevinas M; Llorca J; Castaño-Vinyals G; Penney KL; Stampfer M; Park JY; Sellers TA; Lin HY; Stanford JL; Cybulski C, 2019, 'Correction to: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8)', Nature Genetics, 51, pp. 363, http://dx.doi.org/10.1038/s41588-018-0330-6

Skvortsova K; Masle-Farquhar E; Luu PL; Song JZ; Qu W; Zotenko E; Gould CM; Du Q; Peters TJ; Colino-Sanguino Y; Pidsley R; Nair SS; Khoury A; Smith GC; Miosge LA; Reed JH; Kench JG; Rubin MA; Horvath L; Bogdanovic O; Lim SM; Polo JM; Goodnow CC; Stirzaker C; Clark SJ, 2019, 'DNA Hypermethylation Encroachment at CpG Island Borders in Cancer Is Predisposed by H3K4 Monomethylation Patterns', Cancer Cell, 35, pp. 297 - 314.e8, http://dx.doi.org/10.1016/j.ccell.2019.01.004

Stockler MR; Martin AJ; Dhillon H; Davis ID; Chi KN; Chowdhury S; Horvath LG; Lawrence NJ; Marx GM; Caffrey JM; McDermott R; North SA; Parnis F; Pook DW; Reaume MN; Sandhu SK; Tan TH; Thomson A; Zielinski R; Sweeney CJ, 2019, 'Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial', Annals of Oncology, 30, pp. v886 - v887, http://dx.doi.org/10.1093/annonc/mdz394.046

Stradella A; Johnson ML; Goel S; Chandana SR; Galsky MD; Calvo E; Moreno V; Park H; Arkenau H-T; Cervantes A; Madrid LF; Mileshkin L; Plummer R; Evans J; Horvath L; Prawira A; Pelham RJ; Mu S; Andreu-Vieyra C; Barve M, 2019, 'Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours', Annals of Oncology, 30, pp. v166 - v167, http://dx.doi.org/10.1093/annonc/mdz244.013

Sweeney C; Martin AJ; Zielinski RR; Thomson A; Tan TH; Sandhu SK; Reaume MN; Pook DW; Parnis F; North SA; McDermott R; McCaffrey J; Marx GM; Lawrence NJ; Horvath L; Frydenberg M; Chowdhury S; Chi KN; Stockler MR; Davis ID, 2019, 'Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone -sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.18_suppl.LBA2

Tran B; Kouros-Mehr H; Fermin A; Horvath L; Roncolato F; Rettig M; Dorff T; Tagawa ST; Subudhi SK; Antonarakis ES; Armstrong AJ; Petrylak DP; Fizazi K; Salvati ME; Scher HI, 2019, 'A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)', Annals of Oncology, 30, pp. v353 - v353, http://dx.doi.org/10.1093/annonc/mdz248.052

Zhang AY; Chiam K; Haupt Y; Fox S; Birch S; Tilley W; Butler LM; Knudsen K; Comstock C; Rasiah K; Grogan J; Mahon KL; Bianco-Miotto T; Ricciardelli C; Böhm M; Henshall S; Delprado W; Stricker P; Horvath LG; Kench JG, 2019, 'An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy', International Journal of Cancer, 144, pp. 1151 - 1159, http://dx.doi.org/10.1002/ijc.31906

Dadaev T; Saunders EJ; Newcombe PJ; Anokian E; Leongamornlert DA; Brook MN; Cieza-Borrella C; Mijuskovic M; Wakerell S; Olama AAA; Schumacher FR; Berndt SI; Benlloch S; Ahmed M; Goh C; Sheng X; Zhang Z; Muir K; Govindasami K; Lophatananon A; Stevens VL; Gapstur SM; Carter BD; Tangen CM; Goodman P; Thompson IM; Batra J; Chambers S; Moya L; Clements J; Horvath L; Tilley W; Risbridger G; Gronberg H; Aly M; Nordström T; Pharoah P; Pashayan N; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Albanes D; Weinstein S; Wolk A; Hakansson N; West C; Dunning AM; Burnet N; Mucci L; Giovannucci E; Andriole G; Cussenot O; Cancel-Tassin G; Koutros S; Freeman LEB; Sorensen KD; Orntoft TF; Borre M; Maehle L; Grindedal EM; Neal DE; Donovan JL; Hamdy FC; Martin RM; Travis RC; Key TJ; Hamilton RJ; Fleshner NE; Finelli A; Ingles SA; Stern MC; Rosenstein B; Kerns S; Ostrer H; Lu YJ; Zhang HW; Feng N; Mao X; Guo X; Wang G; Sun Z; Giles GG; Southey MC; MacInnis RJ; Fitzgerald LM; Kibel AS; Drake BF; Vega A; Gómez-Caamaño A; Fachal L; Szulkin R; Eklund M; Kogevinas M; Llorca J; Castaño-Vinyals G; Penney KL; Stampfer M; Park JY; Sellers TA, 2018, 'Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-04109-8

Deva S; Lee J-S; Lin C-C; Yen C-J; Millward M; Chao Y; Keam B; Jameson M; Hou M-M; Kang Y-K; Markman B; Lu C-H; Rau K-M; Lee K-H; Horvath L; Friedlander M; Hill A; Wu J; Hou J; Desai J, 2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', Annals of Oncology, 29, pp. x24 - x25, http://dx.doi.org/10.1093/annonc/mdy487.042

Kalsbeek AMF; Chan EKF; Grogan J; Petersen DC; Jaratlerdsiri W; Gupta R; Lyons RJ; Haynes AM; Horvath LG; Kench JG; Stricker PD; Hayes VM, 2018, 'Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer', Prostate, 78, pp. 25 - 31, http://dx.doi.org/10.1002/pros.23440

Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ, 2018, 'Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer', Prostate, 78, pp. 308 - 317, http://dx.doi.org/10.1002/pros.23476

Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A, 2018, 'MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-26050-y

Matejcic M; Saunders EJ; Dadaev T; Brook MN; Wang K; Sheng X; Olama AAA; Schumacher FR; Ingles SA; Govindasami K; Benlloch S; Berndt SI; Albanes D; Koutros S; Muir K; Stevens VL; Gapstur SM; Tangen CM; Batra J; Clements J; Gronberg H; Pashayan N; Schleutker J; Wolk A; West C; Mucci L; Kraft P; Cancel-Tassin G; Sorensen KD; Maehle L; Grindedal EM; Strom SS; Neal DE; Hamdy FC; Donovan JL; Travis RC; Hamilton RJ; Rosenstein B; Lu YJ; Giles GG; Kibel AS; Vega A; Bensen JT; Kogevinas M; Penney KL; Park JY; Stanford JL; Cybulski C; Nordestgaard BG; Brenner H; Maier C; Kim J; Teixeira MR; Neuhausen SL; De Ruyck K; Razack A; Newcomb LF; Lessel D; Kaneva R; Usmani N; Claessens F; Townsend PA; Dominguez MG; Roobol MJ; Menegaux F; Khaw KT; Cannon-Albright LA; Pandha H; Thibodeau SN; Schaid DJ; Henderson BE; Stern MC; Thwaites A; Guy M; Whitmore I; Morgan A; Fisher C; Hazel S; Livni N; Cook M; Fachal L; Weinstein S; Beane Freeman LE; Hoover RN; Machiela MJ; Lophatananon A; Carter BD; Goodman P; Moya L; Srinivasan S; Kedda MA; Yeadon T; Eckert A; Eklund M; Cavalli-Bjoerkman C; Dunning AM; Sipeky C; Hakansson N; Elliott R; Ranu H, 2018, 'Germline variation at 8q24 and prostate cancer risk in men of European ancestry', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-06863-1

Nair SS; Luu PL; Qu W; Maddugoda M; Huschtscha L; Reddel R; Chenevix-Trench G; Toso M; Kench JG; Horvath LG; Hayes VM; Stricker PD; Hughes TP; White DL; Rasko JEJ; Wong JJL; Clark SJ, 2018, 'Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten', Epigenetics and Chromatin, 11, http://dx.doi.org/10.1186/s13072-018-0194-0

Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM, 2018, 'Identification of novel response and predictive biomarkers to Hsp90 inhibitors through proteomic profiling of patient-derived prostate tumor explants', Molecular and Cellular Proteomics, 17, pp. 1470 - 1486, http://dx.doi.org/10.1074/mcp.RA118.000633

Pidsley R; Lawrence MG; Zotenko E; Niranjan B; Statham A; Song J; Chabanon RM; Qu W; Wang H; Richards M; Nair SS; Armstrong NJ; Nim HT; Papargiris M; Balanathan P; French H; Peters T; Norden S; Ryan A; Pedersen J; Kench J; Daly RJ; Horvath LG; Stricker P; Frydenberg M; Taylor RA; Stirzaker C; Risbridger GP; Clark SJ, 2018, 'Enduring epigenetic landmarks define the cancer microenvironment', Genome Research, 28, pp. 625 - 638, http://dx.doi.org/10.1101/gr.229070.117

Roohullah A; Cooper A; Lomax AJ; Aung J; Barge A; Chow L; McHale M; Desai J; Whittle JR; Tran B; de Souza P; Horvath LG, 2018, 'A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers', Investigational New Drugs, 36, pp. 886 - 894, http://dx.doi.org/10.1007/s10637-018-0588-7

Schumacher FR; Al Olama AA; Berndt SI; Benlloch S; Ahmed M; Saunders EJ; Dadaev T; Leongamornlert D; Anokian E; Cieza-Borrella C; Goh C; Brook MN; Sheng X; Fachal L; Dennis J; Tyrer J; Muir K; Lophatananon A; Stevens VL; Gapstur SM; Carter BD; Tangen CM; Goodman PJ; Thompson IM; Batra J; Chambers S; Moya L; Clements J; Horvath L; Tilley W; Risbridger GP; Gronberg H; Aly M; Nordström T; Pharoah P; Pashayan N; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Albanes D; Weinstein S; Wolk A; Håkansson N; West CML; Dunning AM; Burnet N; Mucci LA; Giovannucci E; Andriole GL; Cussenot O; Cancel-Tassin G; Koutros S; Beane Freeman LE; Sorensen KD; Orntoft TF; Borre M; Maehle L; Grindedal EM; Neal DE; Donovan JL; Hamdy FC; Martin RM; Travis RC; Key TJ; Hamilton RJ; Fleshner NE; Finelli A; Ingles SA; Stern MC; Rosenstein BS; Kerns SL; Ostrer H; Lu YJ; Zhang HW; Feng N; Mao X; Guo X; Wang G; Sun Z; Giles GG; Southey MC; MacInnis RJ; Fitzgerald LM; Kibel AS; Drake BF; Vega A; Gómez-Caamaño A; Szulkin R; Eklund M; Kogevinas M; Llorca J; Castaño-Vinyals G; Penney KL; Stampfer M; Park JY; Sellers TA; Lin HY; Stanford JL; Cybulski C, 2018, 'Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci', Nature Genetics, 50, pp. 928 - 936, http://dx.doi.org/10.1038/s41588-018-0142-8

Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; Lopez-Gitlitz A; Trudel GC; Espina BM; Shu Y; Park YC; Rackoff WR; Yu MK; Small EJ, 2018, 'Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer', New England Journal of Medicine, 378, pp. 1408 - 1418, http://dx.doi.org/10.1056/nejmoa1715546

Timmins HC; Li T; Grimison P; Murray JE; Cox KM; Horvath LG; Lewis CR; Goldstein D; Kiernan MC; Park SB, 2018, '5. Neurophysiological dysfunction in chemotherapy-treated patients: Comparison of different platinum analogues', Clinical Neurophysiology, 129, pp. e2 - e3, http://dx.doi.org/10.1016/j.clinph.2017.12.018

Vafaee F; Diakos C; Kirschner M; Reid G; Michael M; Horvath LISA; Alinejad-Rokny H; Cheng ZJ; Kuncic Z; Clarke S, 2018, 'A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis', npj Systems Biology and Applications, 4, pp. 20 - 20, http://dx.doi.org/10.1038/s41540-018-0056-1

Barnet MB; O'Toole S; Horvath LG; Selinger C; Yu B; Ng CC; Boyer M; Cooper WA; Kao S, 2017, 'EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors', Journal of Thoracic Oncology, 12, pp. 585 - 590, http://dx.doi.org/10.1016/j.jtho.2016.09.001

Grogan J; Gupta R; Mahon KL; Stricker PD; Haynes AM; Delprado W; Turner J; Horvath LG; Kench JG, 2017, 'Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up', BJU International, 120, pp. 651 - 658, http://dx.doi.org/10.1111/bju.13857

Horvath L; Desai J; Sandhu S; O'Donnell A; Hill AG; Deva S; Markman B; Jameson MB; Chen Z; Tan X; Hou J; Lim A, 2017, 'Preliminary results from a subset of patients (pts) with advanced head and neck squamous carcinoma (HNSCC) in a dose-escalation and dose-expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', Annals of Oncology, 28, pp. v129 - v130, http://dx.doi.org/10.1093/annonc/mdx367.022

Kalsbeek A; Chan E; Grogan J; Petersen D; Jaratlerdsiri W; Gupta R; Lyons R; Haynes A-M; Horvath L; Kench J; Stricker P; Hayes V, 2017, 'MP83-01 HIGH-GRADE PROSTATE CANCER HAS INCREASED MITOCHONDRIAL CONTENT', Journal of Urology, 197, http://dx.doi.org/10.1016/j.juro.2017.02.2569

Kandula T; Farrar MA; Kiernan MC; Krishnan AV; Goldstein D; Horvath L; Grimison P; Boyle F; Baron-Hay S; Park SB, 2017, 'Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer', Clinical Neurophysiology, 128, pp. 1166 - 1175, http://dx.doi.org/10.1016/j.clinph.2017.04.009

Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler MR; Bastick P; Briscoe K; Marx G; Swarbrick A; Horvath LG, 2017, 'Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer', British Journal of Cancer, 116, pp. 1002 - 1011, http://dx.doi.org/10.1038/bjc.2017.50

Lin HM; Mahon KL; Weir JM; Mundra PA; Spielman C; Briscoe K; Gurney H; Mallesara G; Marx G; Stockler MR; Prime C; Parton RG; Hoy AJ; Daly RJ; Meikle PJ; Horvath LG, 2017, 'A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer', International Journal of Cancer, 141, pp. 2112 - 2120, http://dx.doi.org/10.1002/ijc.30903

Mahon KL; Qu W; Lin H-M; Spielman C; Cain D; Jacobs C; Chi KN; De Bono JS; Higano CS; Clark SJ; Horvath L, 2017, 'Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 35, pp. 5014 - 5014, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5014

McCrary JM; Goldstein D; Boyle F; Cox K; Grimison P; Kiernan MC; Krishnan AV; Lewis CR; Webber K; Baron-Hay S; Horvath L; Park SB, 2017, 'Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey', Supportive Care in Cancer, 25, pp. 3485 - 3493, http://dx.doi.org/10.1007/s00520-017-3772-y

Meniawy T; Richardson G; Townsend A; Desai J; Gan H; Friedlander M; Horvath L; Jameson MB; Sandhu S; Wu Z; Qin Z; Kang K; Markman B, 2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', Annals of Oncology, 28, pp. v130 - v130, http://dx.doi.org/10.1093/annonc/mdx367.023

Nikolic I; Elsworth B; Dodson E; Wu SZ; Gould CM; Mestdagh P; Marshall GM; Horvath LG; Simpson KJ; Swarbrick A, 2017, 'Discovering cancer vulnerabilities using high-throughput micro-RNA screening', Nucleic Acids Research, 45, pp. 12657 - 12670, http://dx.doi.org/10.1093/nar/gkx1072

Quinn DI; Sandler HM; Horvath LG; Goldkorn A; Eastham JA, 2017, 'The evolution of chemotherapy for the treatment of prostate cancer', Annals of Oncology, 28, pp. 2658 - 2669, http://dx.doi.org/10.1093/annonc/mdx348

Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MRJ; O'Toole SA; Cooper WA, 2017, 'Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target', Histopathology, 70, pp. 402 - 411, http://dx.doi.org/10.1111/his.13076

Valdés-Mora F; Gould CM; Colino-Sanguino Y; Qu W; Song JZ; Taylor KM; Buske FA; Statham AL; Nair SS; Armstrong NJ; Kench JG; Lee KML; Horvath LG; Qiu M; Ilinykh A; Yeo-Teh NS; Gallego-Ortega D; Stirzaker C; Clark SJ; Valdes Mora F; Colino Sanguino Y; Sasidharan-Nair S, 2017, 'Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer', Nature Communications, 8, pp. 1346, http://dx.doi.org/10.1038/s41467-017-01393-8

Zhang AY; Grogan JS; Mahon KL; Rasiah K; Sved P; Eisinger DR; Boulas J; Vasilaris A; Henshall SM; Stricker PD; Kench JG; Horvath LG, 2017, 'A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer', Annals of Oncology, 28, pp. 1903 - 1909, http://dx.doi.org/10.1093/annonc/mdx247

2017, 'Mitochondrial genome content is decreased in prostate cancer overall, but increased in high grade cancer', Pathology, 49, pp. S104 - S105, http://dx.doi.org/10.1016/j.pathol.2016.12.300

Bonilla C; Lewis SJ; Martin RM; Donovan JL; Hamdy FC; Neal DE; Eeles R; Easton D; Kote-Jarai Z; Al Olama AA; Benlloch S; Muir K; Giles GG; Wiklund F; Gronberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Pashayan N; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park J; Kaneva R; Batra J; Teixeira MR; Pandha H; Lathrop M; Smith GD; Cook M; Morga A; Lophatananon A; Fisher C; Leongamornlert D; Saunders EJ; Sawyer EJ; Govindasami K; Tymrakiewicz M; Guy M; Livni N; Wilkinson R; Jugurnauth-Little S; Hazel S; Dadaev T; Southey MC; Fitzgerald LM; Pedersen J; Hopper J; Karlsson A; Cavalli-Bjoerkman C; Johansson JE; Adolfson J; Aly M; Broms M; Stattin P; Henderson BE; Schumacher F; Auvinen A; Taari K; Maeaettaenen L; Kujala P; Murtola T; Tammela TLJ; Sipeky C; Roder MA; Iversen P; Klarskov P; Nielsen SF; Weischer M; Key TJ; Wallinder H; Gustafsson S; Cox A; George A; Lane A; Marsden G; Davis M; Brown P; Pharoah P; Signorello LB; Zheng W; McDonnell SK; Schaid DJ; Wang L; Tillmans L; Riska S; Schnoeller T; Herkommer K; Luedeke M; Vogel W; Wokozorczyk D; Lubiski J; Kluzniak W; Horvath L, 2016, 'Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort', BMC Medicine, 14, pp. 66, http://dx.doi.org/10.1186/s12916-016-0602-x

Bruce HM; Stricker PD; Gupta R; Savdie RR; Haynes AM; Mahon KL; Lin HM; Kench JG; Horvath LG, 2016, 'Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer', Prostate, 76, pp. 1491 - 1500, http://dx.doi.org/10.1002/pros.23233

Fromm PD; Papadimitrious MS; Hsu JL; Van Kooten Losio N; Verma ND; Lo TH; Silveira PA; Bryant CE; Turtle CJ; Prue RL; Vukovic P; Munster DJ; Nagasaki T; Barnard RT; Mahler SM; Anguille SA; Berneman Z; Horvath LG; Bradstock KF; Joshua DE; Clark GJ; Hart DNJ, 2016, 'CMRF-56⁺ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses', OncoImmunology, 5, http://dx.doi.org/10.1080/2162402X.2016.1168555

Humphrey ES; Su SP; Nagrial AM; Hochgrä Fe F; Pajic M; Lehrbach GM; Parton RG; Yap AS; Horvath LG; Chang DK; Biankin AV; Wu J; Daly RJ, 2016, 'Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling', Molecular and Cellular Proteomics, 15, pp. 2671 - 2685, http://dx.doi.org/10.1074/mcp.M116.058313

Kalsbeek AMF; Chan EFK; Grogan J; Petersen DC; Jaratlerdsiri W; Gupta R; Lyons RJ; Haynes AM; Horvath LG; Kench JG; Stricker PD; Hayes VM, 2016, 'Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer', Aging, 8, pp. 2702 - 2712, http://dx.doi.org/10.18632/aging.101044

Lomax AJ; Beith J; Bhadri V; Boyer M; Grimison P; Horvath LG; Kao S; Tattersall M; Thomas D; McNeil C, 2016, 'Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse', Internal Medicine Journal, 46, pp. 1392 - 1398, http://dx.doi.org/10.1111/imj.13232

Mahon KL; Lin H-M; Spielman C; Lee-Ng M; Gurney H; Mallesara G; Stockler MR; Briscoe KP; Marx GM; Breit SN; Brown DA; Horvath L, 2016, 'Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 34, pp. 5039 - 5039, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.5039

Papadimitrious M; Fromm PD; Van Kooten Losio N; Bryant C; Clark GJ; Anguille S; Berneman ZN; Horvath L; Bradstock KF; Hart DN, 2016, 'mRNA Loaded CMRF-56 Blood Dendritic Cells Augment Anti-Cancer Immune Responses in Conjunction with Nivolumab', Cytotherapy, 18, pp. S100 - S100, http://dx.doi.org/10.1016/j.jcyt.2016.03.205

Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip PY; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA, 2015, 'PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma', Lung Cancer, 89, pp. 181 - 188, http://dx.doi.org/10.1016/j.lungcan.2015.05.007

Gupta R; O'Connell R; Haynes A-M; Stricker PD; Barrett W; Turner JJ; Delprado W; Horvath LG; Kench JG, 2015, 'Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?', BJU International, pp. n/a - n/a, http://dx.doi.org/10.1111/bju.12911

Lee BY; Timpson P; Horvath LG; Daly RJ, 2015, 'FAK signaling in human cancer as a target for therapeutics', Pharmacology & therapeutics, 146, pp. 132 - 149, http://dx.doi.org/10.1016/j.pharmthera.2014.10.001

Mahon KL; Lin HM; Castillo L; Lee BY; Lee-Ng M; Chatfield MD; Chiam K; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Daly RJ; Henshall SM; Horvath LG, 2015, 'Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer', British Journal of Cancer, 112, pp. 1340 - 1348, http://dx.doi.org/10.1038/bjc.2015.74

Nagrial AM; Chin VT; Sjoquist KM; Pajic M; Horvath LG; Biankin AV; Yip D, 2015, 'Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials', Critical Reviews in Oncology/Hematology, 96, pp. 483 - 497, http://dx.doi.org/10.1016/j.critrevonc.2015.07.007

Rynkiewicz NK; Fedele CG; Chiam K; Gupta R; Kench JG; Ooms LM; McLean CA; Giles GG; Horvath LG; Mitchell CA, 2015, 'INPP4Bis highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival', Prostate, 75, pp. 92 - 102, http://dx.doi.org/10.1002/pros.22895

Stegeman S; Amankwah E; Klein K; O’Mara TA; Kim D; Lin HY; Permuth-Wey J; Sellers TA; Srinivasan S; Eeles R; Easton D; Kote-Jarai Z; Al Olama AA; Benlloch S; Muir K; Giles GG; Wiklund F; Gronberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Neal D; Pharoah P; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Kaneva R; Teixeira MR; Spurdle AB; Clements JA; Park JY; Batra J; Cook M; Morgan A; Lophatananon A; Fisher C; Leongamornlert D; Saunders EJ; Sawyer EJ; Govindasami K; Tymrakiewicz M; Guy M; Livni N; Wilkinson R; Jugurnauth-Little S; Hazel S; Dadaev T; Pedersen J; Hopper JL; Southey MC; Karlsson A; Cavalli-Bjoerkman C; Johansson JE; Adolfson J; Aly M; Broms M; Stattin P; Henderson BE; Schumacher F; Auvinen A; Taari K; Maeaettaenen L; Kujala P; Murtola T; Tammela TLJ; Wahlfors T; Roder A; Iversen P; Klarskov P; Nielsen SF; Weischer M; Key TJ; Wallinder H; Gustafsson S; Donovan JL; Hamdy F; George A; Lane A; Marsden G; Davis M; Brown P; Pashayan N; Holt S; Signorello LB; Zheng W; Wang L; Tillmans L; Riska S; Rinckleb A; Herkommer K; Luedeke M, 2015, 'A large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer', Cancer Discovery, 5, pp. 368 - 379, http://dx.doi.org/10.1158/2159-8290.CD-14-1057

Szulkin R; Whitington T; Eklund M; Aly M; Eeles RA; Easton D; Kote-Jarai Z; Al Olama AA; Benlloch S; Muir K; Giles GG; Southey MC; Fitzgerald LM; Henderson BE; Schumacher F; Haiman CA; Schleutker J; Wahlfors T; Tammela TLJ; Nordestgaard BG; Key TJ; Travis RC; Neal DE; Donovan JL; Hamdy FC; Pharoah P; Pashayan N; Khaw K-T; Stanford JL; Thibodeau SN; McDonnell SK; Schaid DJ; Maier C; Vogel W; Luedeke M; Herkommer K; Kibel AS; Cybulski C; Lubinski J; Kluzniak W; Cannon-Albright L; Brenner H; Butterbach K; Stegmaier C; Park JY; Sellers T; Lim H-Y; Slavov C; Kaneva R; Mitev V; Batra J; Clements JA; Spurdle A; Teixeira MR; Paulo P; Maia S; Pandha H; Michael A; Kierzek A; Gronberg H; Wiklund F, 2015, 'Prediction of Individual Genetic Risk to Prostate Cancer Using a Polygenic Score', PROSTATE, 75, pp. 1467 - 1474, http://dx.doi.org/10.1002/pros.23037

Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G, 2015, 'Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions', Clinical Oncology, 27, pp. 700 - 707, http://dx.doi.org/10.1016/j.clon.2015.08.006

Birch SE; Kench JG; Takano E; Chan P; Chan A-L; Chiam K; Veillard A-S; Stricker P; Haupt S; Haupt Y; Horvath L; Fox SB, 2014, 'Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death', Annals of Oncology, 25, pp. 2392 - 2397, http://dx.doi.org/10.1093/annonc/mdu454

Cooper WA; Selinger CI; Tran TN; Pavlakis N; Yip PY; Horvath L; Kohonen-Corish MR; O'Toole S, 2014, '11. Ros1 gene rearrangements in non-small cell lung carcinoma - a new genetic target.', Pathology, 46 Suppl 1, pp. S110, http://dx.doi.org/10.1097/01.PAT.0000443701.27695.95

Galletti G; Matov A; Beltran H; Fontugne J; Miguel Mosquera J; Cheung C; Macdonald TY; Sung M; O'Toole S; Kench JG; Suk Chae S; Kimovski D; Tagawa ST; Nanus DM; Rubin MA; Horvath LG; Giannakakou P; Rickman DS, 2014, 'ERG induces taxane resistance in castration-resistant prostate cancer', Nature Communications, 5, http://dx.doi.org/10.1038/ncomms6548

Grimison P; Stockler MR; Yip S; Toner G; Horvath L, 2014, 'Anzup 1302 P3Bep Companion Translational Study: Prospective Collection of Whole Blood, Serum, Plasma and Tumour Tissue in a Randomized Trial of Chemotherapy for Metastatic Germ Cell Tumours (Gct)', Annals of Oncology, 25, pp. iv304 - iv304, http://dx.doi.org/10.1093/annonc/mdu337.67

Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG, 2014, 'Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer', British Journal of Cancer, 110, pp. 2462 - 2471, http://dx.doi.org/10.1038/bjc.2014.181

Mahon KL; Qu W; Devaney J; Paul C; Castillo L; Wykes RJ; Chatfield MD; Boyer MJ; Stockler MR; Marx G; Gurney H; Mallesara G; Molloy PL; Horvath LG; Clark SJ, 2014, 'Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer', British Journal of Cancer, 111, pp. 1802 - 1809, http://dx.doi.org/10.1038/bjc.2014.463

Nagrial AM; Chang DK; Nguyen NQ; Johns AL; Chantrill LA; Humphris JL; Chin VT; Samra JS; Gill AJ; Pajic M; Pinese M; Colvin EK; Scarlett CJ; Chou A; Kench JG; Sutherland RL; Horvath LG; Biankin AV, 2014, 'Adjuvant chemotherapy in elderly patients with pancreatic cancer', British Journal of Cancer, 110, pp. 313 - 319, http://dx.doi.org/10.1038/bjc.2013.722

Sutherland SIM; Pe Benito R; Henshall SM; Horvath LG; Kench JG, 2014, 'Expression of phosphorylated-mTOR during the development of prostate cancer', Prostate, 74, pp. 1231 - 1239, http://dx.doi.org/10.1002/pros.22840

Suttie CF; Hruby G; Horvath L; Thompson J, 2014, 'Cardiac metastasis in Merkel cell carcinoma', Journal of Clinical Oncology, 32, http://dx.doi.org/10.1200/JCO.2012.48.3073

Yip PY; Cooper WA; Kohonen-Corish MRJ; Lin BPC; McCaughan BC; Boyer MJ; Kench JG; Horvath LG, 2014, 'Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer', Journal of Clinical Pathology, 67, pp. 333 - 340, http://dx.doi.org/10.1136/jclinpath-2013-201870

Cooper WA; Selinger CI; Tran TN; Pavlakis N; Yip PY; Horvath LG; Kohonen-Corish M; O'Toole S, 2013, 'ROS1 GENE REARRANGEMENTS IN NON-MALL CELL LUNG CARCINOMA - A NEW GENETIC TARGET THAT CAN BE IDENTIFIED BY IMMUNOHISTOCHEMISTRY AND FISH', JOURNAL OF THORACIC ONCOLOGY, 8, pp. S1251 - S1251, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339624906085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MRJ; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA, 2013, 'EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma', Journal of Clinical Pathology, 66, pp. 744 - 748, http://dx.doi.org/10.1136/jclinpath-2013-201607

Harland S; Staffurth J; Molina A; Hao Y; Gagnon DD; Sternberg CN; Cella D; Fizazi K; Logothetis CJ; Kheoh T; Haqq CM; de Bono JS; Scher HI, 2013, 'Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy', EUROPEAN JOURNAL OF CANCER, 49, pp. 3648 - 3657, http://dx.doi.org/10.1016/j.ejca.2013.07.144

Horvath L; Chatfield MD; Lee-Ng M; Lin H-M; Castillo L; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Wykes R; Henshall SM; Mahon KL, 2013, 'The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).', Journal of Clinical Oncology, 31, pp. e22175 - e22175, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22175

Hulf T; Sibbritt T; Wiklund ED; Patterson K; Song JZ; Stirzaker C; Qu W; Nair S; Horvath LG; Armstrong NJ; Kench JG; Sutherland RL; Clark SJ, 2013, 'Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer', Oncogene, 32, pp. 2891 - 2899, http://dx.doi.org/10.1038/onc.2012.300

Lee BY; Hochgraefe F; Lin H-M; Castillo L; Wu J; Raftery M; Shreeve SM; Horvath L; Daly R, 2013, 'Focal adhesion kinase: a mediator of docetaxel-resistance in castrate resistant prostate cancer', BJU INTERNATIONAL, 112, pp. 38 - 39, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000321969100100&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lee BY; Hochgräfe F; Lin HM; Castillo L; Wu J; Raftery MJ; Martin Shreeve S; Horvath LG; Daly RJ, 2013, 'Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer', Molecular Cancer Therapeutics, 13, pp. 190 - 201, http://dx.doi.org/10.1158/1535-7163.MCT-13-0225-T

Ryan C; Smith M; de Bono J; Molina A; Logothetis D; De Souza P; et A, 2013, 'Abiraterone in metastatic prostate cancer without previous chemotherapy', New England Journal of Medicine, 368, pp. 138 - 148, http://dx.doi.org/10.1056/NEJMoa1209096

Selinger CI; Rogers TM; Russell PA; O'Toole S; Yip PY; Wright GM; Wainer Z; Horvath LG; Boyer M; McCaughan B; Kohonen-Corish MRJ; Fox S; Cooper WA; Solomon B, 2013, 'Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization', Modern Pathology, 26, pp. 1545 - 1553, http://dx.doi.org/10.1038/modpathol.2013.87

Selth L; Townley S; Bert A; Stricker P; Sutherland P; Horvath L; Goodall G; Butler L; Tilley W, 2013, 'CIRCULATING microRNAs PREDICT BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 9, pp. 63 - 63, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Stricker PD; Selth L; Townley S; Bert A; Sutherland P; Horvath L; Goodall G; Butler L; Tilley W, 2013, 'Circulating microRNAs predict biochemical recurrence in prostate cancer patients.', British Journal of Cancer, pp. 641 - 650, http://dx.doi.org/10.1038/bjc.2013.369

Sutherland S; Henshall S; Horvath L; Kench J, 2013, 'THE ROLE OF MAMMALIAN TARGET OF RAPAMYCIN (mTOR) IN THE DEVELOPMENT OF PROSTATE CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 9, pp. 49 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yip PY; Cooper WA; Kohonen-Corish M; Mccaughan B; Boyer M; Kench J; Horvath LG, 2013, 'PHOSPHORYLATED-AKT EXPRESSION IS A PROGNOSTIC MARKER IN EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)', JOURNAL OF THORACIC ONCOLOGY, 8, pp. S785 - S785, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339624903324&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yip PY; Yu B; Cooper W; Selinger CI; Ng C; Kennedy C; Kohonen-Corish M; McCaughan BC; Trent RJ; Boyer MJ; Kench JG; Horvath LG; O'Toole S, 2013, 'Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma', Journal of Thoracic Oncology, 8, pp. 408 - 414, http://dx.doi.org/10.1097/JTO.0b013e318283558e

Yu B; Mercorella B; Irwin D; Ng CC; Hunt P; Yip PY; Kohonen-Corish M; Horvath LG; Cooper WA; Trent RJ; O'Toole S, 2013, 'SIMULTANEOUS PROFILING OF MULTIGENE MUTATIONS FOR THE EFFECTIVE AND EFFICIENT DIAGNOSIS OF NON-SMALL CELL LUNG CARCINOMA', JOURNAL OF THORACIC ONCOLOGY, 8, pp. S784 - S785, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339624903322&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Chua W; Horvath L; Beale P; Clarke SJ, 2012, 'Reporting clinical trial information: Colorectal cancer trials at Sydney Cancer Centre', Internal Medicine Journal, 42, pp. 416 - 421, http://dx.doi.org/10.1111/j.1445-5994.2011.02441.x

Cooper WA; Yu B; Yip PY; Farzin M; Clarkson A; Kohonen-Corish MJ; Horvath L; Kench JG; McCaughan B; O'Toole SA; Gill AJ, 2012, 'EGFR MUTANT SPECIFIC IMMUNOHISTOCHEMISTRY HAS HIGH SPECIFICITY BUT ONLY MODERATE SENSITIVITY FOR DETECTING COMMON ACTIVATING EGFR MUTATIONS IN LUNG ADENOCARCINOMA', JOURNAL OF THORACIC ONCOLOGY, 7, pp. S162 - S162, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000317034900018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Femia G; Hardy TA; Spies JM; Horvath LG, 2012, 'Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: A case report and literature review', Asia-Pacific Journal of Clinical Oncology, 8, pp. 115 - 122, http://dx.doi.org/10.1111/j.1743-7563.2012.01544.x

Fizazi K; Scher HI; Molina A; Logothetis CJ; Chi KN; Jones RJ; Staffurth JN; North S; Vogelzang NJ; Saad F; Mainwaring P; Harland S; Goodman OB; Sternberg CN; Li JH; Kheoh T; Haqq CM; de Bono JS, 2012, 'Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study', LANCET ONCOLOGY, 13, pp. 983 - 992, http://dx.doi.org/10.1016/S1470-2045(12)70379-0

Goldstein D; Spry N; Cummins MM; Brown C; Van Hazel GA; Carroll SL; Selva Nayagam S; Borg M; Ackland S; Wratten C; Shapiro J; Porter L; Hruby G; Horvath LG; Bydder S; Underhill C; Harvey JE; Gebski V, 2012, 'The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer', British Journal of Cancer, 106, pp. 61 - 69, http://dx.doi.org/10.1038/bjc.2011.526

Lee BY; Hochgrafe F; Raftery M; Horvath LG; Daly RJ, 2012, 'Abstract A33: Characterization of signaling pathways associated with docetaxel resistance in prostate cancer', Cancer Research, 72, pp. A33 - A33, http://dx.doi.org/10.1158/1538-7445.prca2012-a33

Randall SA; Mckay MJ; Pascovici D; Mahon K; Horvath L; Clarke SJ; Molloy MP, 2012, 'Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry', Proteomics - Clinical Applications, 6, pp. 626 - 634, http://dx.doi.org/10.1002/prca.201200039

Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG, 2012, 'High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy', BJU International, 109, pp. 1794 - 1800, http://dx.doi.org/10.1111/j.1464-410X.2011.10572.x

Selinger C; Rogers T; Russell P; Yip P; O'Toole S; Horvath L; Boyer M; McCaughan B; Kohonen-Corish M; Fox S; Cooper W; Solomon B, 2012, 'ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGEMENT IN LUNG ADENOCARCINOMAS - A LARGE MULTICENTRE STUDY OF FISH AND IHC.', JOURNAL OF THORACIC ONCOLOGY, 7, pp. S182 - S182, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000317034900086&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Selinger CI; Rogers T-M; Russell P; Yip P; O’Toole S; Horvath L; Boyer M; McCaughan B; Kohonen-Corish M; Fox S; Cooper W; Solomon B, 2012, 'Testing for anaplastic lymphoma kinase (ALK) rearrangement in lung adenocarcinomas: a multicentre study', Pathology, 44, pp. S95 - S95, http://dx.doi.org/10.1016/s0031-3025(16)32872-0

Venkateswaran LP; Butow PN; Jansen J; Wilcken NRC; Wong MK; Hui R; Szonyi G; Gebski VJ; Naganathan V; Horvath LG; Tattersall MHN, 2012, 'Decision making in older patients with advanced cancer: Does doctor know best?', Medical Journal of Australia, 196, pp. 35 - 39, http://dx.doi.org/10.5694/mja11.10907

Yip PY; Yu B; Cooper WA; Kench JG; Boyer M; Kohonen-Corish MJ; Trent R; McCaughan B; Kennedy C; O'Toole SA; Horvath L, 2012, 'MUTATIONS IN RESECTED NODE-NEGATIVE LUNG ADENOCARCINOMA', JOURNAL OF THORACIC ONCOLOGY, 7, pp. S189 - S190, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000317034900113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yu B; Yip PY; Cooper W; Ng CC; Mercorella B; Le H; Trent R; Kohonen-Corish M; Kennedy C; McCaughan B; Kench J; Boyer M; Horvath L; O’Toole S, 2012, 'Patterns of somatic mutations in an Australian cohort of lung adenocarcinoma', Pathology, 44, pp. S90 - S90, http://dx.doi.org/10.1016/s0031-3025(16)32856-2

Cooper W; O'Toole S; Boyer MJ; Horvath LG; Mahar A, 2011, 'What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements', Pathology, 43, pp. 103 - 115, http://dx.doi.org/10.1097/PAT.0b013e28342629d

De Bono JS; Logothetis CJ; Molina A; Fizazi K; North S; Chu L; Chi KN; Jones RJ; Goodman OB; Saad F; Staffurth JN; Mainwaring P; Harland S; Flaig TW; Hutson TE; Cheng T; Patterson H; Hainsworth JD; Ryan CJ; Sternberg CN; Ellard SL; Flechon A; Saleh M; Scholz M; Efstathiou E; Zivi A; Bianchini D; Loriot Y; Chieffo N; Thian K; Haqq CM; Scher HI, 2011, 'Abiraterone and Increased Survival in Metastatic Prostate Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 364, pp. 1995 - 2005, http://dx.doi.org/10.1056/NEJMoa1014618

Devaney J; Stirzaker C; Qu W; Song JZ; Statham AL; Patterson K; Horvath LG; Tabor B; Coolen MW; Hulf T; Kench JG; Henshall SM; Pe benito R; Haynes AM; Mayor R; Peinado M; Sutherland RL; Clark SJ, 2011, 'Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers', Cancer Epidemiology Biomarkers and Prevention, 20, pp. 148 - 159, http://dx.doi.org/10.1158/1055-9965.EPI-10-0719

Horvath L; Mahon KL; Qu W; Devaney J; Chatfield MD; Paul C; Wykes R; Boyer MJ; Stockler MR; Marx GM; Sutherland RL; Clark SJ, 2011, 'A study of methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC).', JOURNAL OF CLINICAL ONCOLOGY, 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4603

Kench JG; Clouston DR; Delprado W; Eade T; Ellis D; Horvath LG; Samaratunga H; Stahl J; Stapleton AMF; Egevad L; Srigley JR; Delahunt B, 2011, 'Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens', Pathology, 43, pp. 410 - 419, http://dx.doi.org/10.1097/PAT.0b013e328348a6b3

Leighl N; Shepherd H; Butow PN; clarke SJ; Mcjannett M; Beale P; Wilken N; Moore M; Chen E; Goldstein D; Horvath LG; Knox J; Krzyzanowska M; Oza AM; Feld R; Hedley D; Xu W; Tattersall MH, 2011, 'Supporting treatment decision-making in advanced cancer: a randomized trial of a decision aid for patients considering chemotherapy in advanced colorectal cancer', Journal of Clinical Oncology, 29, pp. 2077 - 2084, http://dx.doi.org/10.1200/JCO.2010.32.0754

Mahon K; Henshall SM; Horvath LG; Sutherland RL, 2011, 'Pathways of chemotherapy resistance in castration-resistant prostate cancer', Endocrine - Related Cancer, 18, pp. 103 - 123, http://dx.doi.org/10.1530/ERC-10-0343

Mahon KL; Chatfield MD; Lee-Ng M; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Wykes R; Henshall SM; Sutherland RL; Horvath L, 2011, 'Cytokines' profiles to predict chemotherapy outcome in castration-resistant prostate cancer (CRPC).', JOURNAL OF CLINICAL ONCOLOGY, 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4598

Savdie R; Horvath L; Pebenito R; Rasiah K; Haynes AM; Stricker P; Turner J; Delprado W; Henshall S; Sutherland R; Kench J, 2011, 'High Gleason grade carcinoma at a positive margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy', BJU INTERNATIONAL, 107, pp. 20 - 21, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000286596800047&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yip PY; Cooper W; Mahar A; Kench J; Kohonen-Corish MR J; Chatfield M; Boulghourjian A; Kennedy CW; Mccaughan B; Boyer M; Horvath L, 2011, 'MARKERS OF PROGNOSIS IN RESECTED STAGE IB NON-SMALL CELL LUNG CANCER (NSCLC)', JOURNAL OF THORACIC ONCOLOGY, 6, pp. S499 - S499, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208855802235&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yip PY; Kench JG; Rasiah KK; Benito RP; Lee CS; Stricker PD; Henshall SM; Sutherland RL; Horvath LG, 2011, 'Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer', Prostate, 71, pp. 1638 - 1645, http://dx.doi.org/10.1002/pros.21381

Lubner SJ; Mahoney MR; Kolesar JL; LoConte NK; Kim GP; Pitot HC; Philip PA; Picus J; Yong WP; Horvath L; Van Hazel G; Erlichman CE; Holen KD, 2010, 'Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: A phase II consortium study', Journal of Clinical Oncology, 28, pp. 3491 - 3497, http://dx.doi.org/10.1200/JCO.2010.28.4075

Nagrial A; Horvath L, 2010, 'Bone disease in prostate cancer', Asia-Pacific Journal of Clinical Oncology, 6, pp. 3 - 4, http://dx.doi.org/10.1111/j.1743-7563.2010.01281.x

Ocean AJ; Polite B; Christos P; Horvath L; Hamilton A; Matulich D; Chen HX; Sparano JA; Kindler HL, 2010, 'Cetuximab is associated with excessive toxicity when combined with bevacizumab plus mFOLFOX6 in metastatic colorectal carcinoma', Clinical Colorectal Cancer, 9, pp. 290 - 296, http://dx.doi.org/10.3816/CCC.2010.n.042

Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; Van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ; Coates A; O'Connell D; Brown C; Hague W; France A; Hicks S; James R; Masson R; O'Connell R; Pike R; Shoulder J; Stevens L; Tunney V; Vachan B; Wong N; Ackland S; Moylan E; Strickland A; Abdi E; Ransom D; Lowenthal R; Marx G; Nayagam SS; Shannon J; Goldstein D; Karapetis C; Blum R; Eek R; Ward R; Pavlakis N; Wilcken N; Burns I; Wyld D; Underhill C; Claringbold P; Liauw W; Clingan P; Jefford M; Horvath L; McKendrick J; Chong G; Boyce A; Cassidy J; Kirsten F; Clarke S; Guo Y; Innes-Rowe J; Smith A; Williams J; Tournier E; Maliepaard S; Vitullo E; Humm G; Nguyen V; Midolo P; Chorlton C; McDonald L; Oliver L; Sjursen AM; Inglis C; Marafioti T; McCourt J; Howard J; Richards A; Provis A; Rundle A; Whatman A; Emmett L; Raymond B; Byrne S; Withers E; Campbell J; Hodgkins C; Szwajcer M; Parker S; Welby S; Page F; Corker M; Wykes R; Goss C; Whitney S; Oates J, 2010, 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study', Journal of Clinical Oncology, 28, pp. 3191 - 3198, http://dx.doi.org/10.1200/JCO.2009.27.7723

Thanigasalam R; Rasiah KK; Stricker PD; Haynes AM; Sutherland S; Sutherland RL; Henshall SM; Horvath LG, 2010, 'Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram', BJU International, 10, pp. 642 - 647

Yip P; Kench J; Rasiah K; Benito R; Lee C; Henshall S; Sutherland R; Horvath L, 2010, 'Molecular markers that predict for recurrence in men with margin-positive localized prostate cancer', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.4650

2010, '300 CAN THE GLEASON GRADE AT THE SITE OF A POSITIVE MARGIN PREDICT BIOCHEMICAL FAILURE POST RADICAL PROSTATECTOMY?', Journal of Urology, 183, http://dx.doi.org/10.1016/j.juro.2010.02.363

Balanathan P; Williams E; Wang H; Pedersen J; Horvath LG; Achen M; Stacker S; Risbridger G, 2009, 'Elevated level of inhibin-α subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer', British Journal of Cancer, 100, pp. 1784 - 1793

Chua W; Randall S; McKay MJ; Horvath L; Clarke SJ; Molloy MP, 2009, 'Targeted plasma proteome profiling for early prediction of chemotherapy response and toxicity in colorectal cancer (CRC)', Journal of Clinical Oncology, 27, pp. e15063 - e15063, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e15063

Gill A; Johns A; Eckstein R; Samra J; Kaufman A; Chang D; Merrett ND; Cosman PH; Smith RC; Biankin AV; Kench JG, 2009, 'Synoptic reporting improves histopathological assessment of pancreatic resection specimens', Pathology, 41, pp. 161 - 167

Horvath L; Zhao L; Lee B; Brown D; Molloy M; Marx G; Boyer M; Breit S; Sutherland R; Henshall S, 2009, 'Identification of candidate biomarkers of therapeutic response to docetaxel in hormone-refractory prostate cancer by proteomic profiling.', J Clin Oncol, 27, pp. 11010, http://www.ncbi.nlm.nih.gov/pubmed/27963974

Karim RZ; Gerega SK; Yang YH; Horvath L; Spillane A; Carmalt H; Scolyer RA; Lee CS, 2009, 'Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours', Journal of Clinical Pathology, 62, pp. 1016 - 1020, http://dx.doi.org/10.1136/jcp.2009.066977

Moore MM; Chua W; Zhao J; Clarke SJ; Horvath L, 2009, 'Evaluation of plasma total and cleaved cytokeratin 18 as predictive markers of chemotherapy in colorectal cancer.', J Clin Oncol, 27, pp. e15091, http://www.ncbi.nlm.nih.gov/pubmed/27964608

Tattersall MH; Dear R; Jansen J; Shepherd H; Devine R; Horvath LG; Boyer MJ, 2009, 'Second opinions in oncology: the experiences of patients attending the Sydney Cancer Centre', Medical Journal of Australia, 191, pp. 209 - 212, http://www.mja.com.au/public/issues/191_04_170809/tat10235_fm.pdf

Zhao L; Lee BY; Brown DA; Molloy M; Marx GM; Pavlakis N; Boyer MJ; Stockler M; Kaplan W; Breit SN; Sutherland RL; Henshall SM; Horvath LG, 2009, 'Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling', Cancer research, 69, pp. 7696 - 7703

2009, 'Proteins from the wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours', Pathology, 41, pp. 60 - 61, http://dx.doi.org/10.1097/01268031-200941001-00132

Chang DK; Merrett ND; Biankin AV, 2008, 'Improving outcomes for operable pancreatic cancer: is access to safer surgery the problem?', Journal of Gastroenterology and Hepatology, 23, pp. 1036 - 1045

Ho L; Kench JG; Handelsman D; Scheffer G; Stricker PD; Grygiel JJ; Sutherland RL; Henshall SM; Allen J; Horvath LG, 2008, 'Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer', Prostate, 68, pp. 1421 - 1429

Horvath L; Thanigasalam R; Rasiah K; Stricker P; Earnest A; Haynes A; Sutherland S; Sutherland R; Henshall S, 2008, 'Stage migration and the Kattan nomogram', JOURNAL OF CLINICAL ONCOLOGY, 26, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.5162

Marrone J; Fairley CK; Saville M; Bradshaw C; Bowden FJ; Horvath L; Donovan BJ; Chen M; Hocking J, 2008, 'Temporal associations with declining Trichomonas vaginalis diagnosis rates among women in the state of Victoria, Australia, 1947 to 2005', Sexually Transmitted Diseases, 35, pp. 572 - 576, http://dx.doi.org/10.1097/OLQ.0b013e3181666aa3

Sakko A; Butler M; Byers S; Reinboth B; Stahl J; Kench JG; Horvath LG; Sutherland RL; Stricker PD; Henshall SM; Marshall V; Tilley WD; Horsfall DJ; Ricciardelli C, 2008, 'Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse', Cancer epidemiology biomarkers and prevention, 17, pp. 2488 - 2497

Seng T; Currey N; Cooper W; Lee CS; Chan C; Horvath LG; Sutherland RL; Kennedy C; McCaughan B; Kohonen-Corish M, 2008, 'DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma', British Journal of Cancer, 99, pp. 375 - 382, http://dx.doi.org/10.1038/sj.bjc.6604452

Horvath LG; Lelliott J; Kench JG; Soon L; Williams E; Saunders DA; Grygiel JJ; Sutherland RL; Henshall SM, 2007, 'Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer', Prostate, 64 (1), pp. 1081 - 1090

2007, 'MP-11.18: Is there evidence of a continued stage migration in the PSA screening era in an Australian population?', Urology, 70, pp. 99 - 100, http://dx.doi.org/10.1016/j.urology.2007.06.401

Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL, 2006, 'Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy', Journal of the National Cancer Institute, 98, pp. 1420 - 1424, http://dx.doi.org/10.1093/jnci/djj378

Horvath LG; Lelliott J; Kench JG; Lee CS; Grygiel JJ; Henshall SM; Sutherland RL, 2006, 'Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer', EJC Supplements, 4, pp. 120 - 120

Rasiah KK; Kench JG; Gardiner-Garden M; Biankin AV; Golovsky D; Brenner PC; Kooner R; O Neill G; Turner J; Delprado W; Lee CS; Brown DA; Breit SN; Grygiel JJ; Horvath LG; Stricker PD; Sutherland RL; Henshall SM, 2006, 'Aberrant neuropepticle Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis', Cancer epidemiology biomarkers and prevention, 15, pp. 711 - 716

Sharma R; Rivory L; Beale P; Ong S; Horvath L; Clarke SJ, 2006, 'A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer', British Journal of Cancer, 94, pp. 964 - 968, http://dx.doi.org/10.1038/sj.bjc.6603049

Horvath LG; Henshall SM; Lee CS; Kench JG; Golovsky D; Brenner PC; O Neill G; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL, 2005, 'Lower levels of nuclear b-catenin predict for a poorer prognosis in localised prostate cancer', International Journal of Cancer, 113, pp. 415 - 422

Read JA; Beale PJ; Horvath LG; Volker D; Childs A; Smith N; Clarke SJ, 2005, 'Impact of fish-oil supplement on nutritional parameters, inflammation and chemotherapy induced toxicity in colorectal cancer (CRC) patients receiving FOLFIRI- a pilot study', Journal of Clinical Oncology, 23, pp. 8243 - 8243, http://dx.doi.org/10.1200/jco.2005.23.16_suppl.8243

Zeng Y; Opeskin K; Baldwin ME; Horvath LG; Achen MG; Stacker SA; Sutherland RL; Williams ED; Loberg RD; Pienta KJ, 2005, 'Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer', Urologic Oncology: Seminars and Original Investigations, 23, pp. 76, http://dx.doi.org/10.1016/j.urolonc.2004.11.005

Zeng Y; Opeskin K; Horvath LG; Sutherland RL; Williams E, 2005, 'Lymphatic vessel density and lymph node metastasis in prostate cancer', Prostate, 65, pp. 222 - 230

Horvath LG; Henshall SM; Kench JG; Saunders DN; Lee CS; Golovsky D; Brenner PC; O Neill G; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL, 2004, 'Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro', Clinical Cancer Research, 10, pp. 615 - 625, http://www.sciencedirect.com/science/article/B6WVB-4C6K0YK-1KG/2/9870ea381b7532fc0a83fed7069d24d3

Horvath LG; Henshall SM; Kench JG; Turner JJ; Golovsky D; Brenner PC; O Neill G; Kooner R; Stricker PD; Grygiel et A, 2004, 'Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression', Prostate, 59, pp. 234 - 242, http://www.sciencedirect.com/science/article/B6WVB-4C7SGSS-309/2/7b9a758bff091ff595430f8afc3931fd

Horvath LG; Henshall SM; Lee CS; Kench JG; Stricker PD; Grygiel JJ; Sutherland RL, 2004, 'Nuclear beta-catenin as a marker of outcome in localized prostate cancer', Journal of Clinical Oncology, 22, pp. 852S - 852S, http://www.ncbi.nlm.nih.gov/pubmed/28016659

Zeng Y; Opeskin K; Baldwin M; Horvath LG; Achen M; Stacker S; Sutherland RL; Williams E, 2004, 'Expression of vascular endothelial growth factor receptor-3 bylymphatic endothelial cells is associated with lymph node metastasis inprostate cancer', Clinical Cancer Research, 10, pp. 5137 - 5144

2004, '1079: Neuropeptide Y Expression is increased in the Progression from Benign to Malignant Prostate Epithelium and Predicts Outcome after Radical Prostatectomy', Journal of Urology, 171, pp. 284 - 285, http://dx.doi.org/10.1016/s0022-5347(18)38316-2

2004, 'Nuclear beta-catenin as a marker of outcome in localized prostate cancer', Journal of Clinical Oncology, 22, pp. 9570 - 9570, http://dx.doi.org/10.1200/jco.2004.22.14_suppl.9570

2004, 'Nuclear beta-catenin as a marker of outcome in localized prostate cancer', Journal of Clinical Oncology, 22, pp. 9570 - 9570, http://dx.doi.org/10.1200/jco.2004.22.90140.9570

Henshall SM; Afar DE; Hiller J; Horvath LG; Quinn DI; Rasiah KK; Gish K; Willhite D; Kench JG; Gardiner-Garden M; Stricker PD; Sher HI; Grygiel JJ; Agus DB; Mack DH; Sutherland RL, 2003, 'Survival analaysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse', Cancer research, 63, pp. 4196 - 4203

Henshall SM; Afar DE; Rasiah KK; Horvath LG; Gish K; Caras I; Ramakrishnan V; Wong M; Jeffrey U; Kench JG; Quinn DI; Turner JI; Delprado W; Lee CM; Golovsky D; Brenner PC; O Neil G; Kooner R; Stricker PD; Grygiel JJ; Mack DH; Sutherland RL, 2003, 'Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease ot invasive prostate cancer', Oncogene, 22, pp. 6005 - 6012

Horvath LG; McCaughan BC; Stockler M; Boyer MJ, 2002, 'Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours', Internal Medicine Journal, 32, pp. 79 - 83, http://dx.doi.org/10.1046/j.1445-5994.2002.00169.x

Afar D; Henshall S; Gish K; Horvath L; Head D; Sutherland R; Mack D, 2001, 'Identification of immunotherapeutic targets in prostate cancer by genome-wide molecular profiling.', CLINICAL CANCER RESEARCH, 7, pp. 3692S - 3692S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000172121800192&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Horvath L; Bayfield M; Clifford A; Painter D; Clarke S, 2001, 'Case 1. Recurrent laryngeal nerve palsy in mediastinal seminoma', Journal of Clinical Oncology, 19, pp. 909 - 911, http://dx.doi.org/10.1200/jco.2001.19.3.909

Horvath L; Boyer M; Clarke S; Beale P; Beith J; Underhill C; Stockler M; Bishop J, 2001, 'Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer', Lung Cancer, 32, pp. 173 - 178, http://dx.doi.org/10.1016/S0169-5002(00)00218-X

Horvath L; Henshall S, 2001, 'The application of tissue microarrays to cancer research', PATHOLOGY, 33, pp. 125 - 129, http://dx.doi.org/10.1080/003130201200338791

Horvath L; Henshall S, 2001, 'Timely topic: The application of tissue microarrays to cancer research', Pathology, 33, pp. 125 - 129, http://dx.doi.org/10.1080/003130201200338791

Horvath L; McDowell D; Stevens G; Parkinson R; McCarthy S; Boyer M, 2001, 'Case 2. Seminoma of the conus medullaris', Journal of Clinical Oncology, 19, pp. 911 - 915, http://dx.doi.org/10.1200/jco.2001.19.3.911

PATER J; KERDO I; SEBESTYEN L; HORVATH L, 1957, 'Complex examinations on industrial hygiene in the workshops of the Hungarian Railways.', Népegészségügy, 38, pp. 26 - 38

HORVATH LG, 1955, 'Effect of fatigue on city workers.', Népegészségügy, 36, pp. 212 - 217

Gillessen S; Turco F; Davis ID; Efstathiou JA; Fizazi K; James ND; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Zilli T; Agarwal N; Antonarakis ES; Aparicio A; Armstrong AJ; Bastos DA; Attard G; Axcrona K; Ayadi M; Beltran H; Bjartell A; Blanchard P; Bourlon MT; Briganti A; Bulbul M; Buttigliero C; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Clarke CS; Clarke N; de Bono JS; De Santis M; Duran I; Efstathiou E; Ekeke ON; El Nahas TIH; Emmett L; Fanti S; Fatiregun OA; Feng FY; Fong PCC; Fonteyne V; Fossati N; George DJ; Gleave ME; Gravis G; Halabi S; Heinrich D; Herrmann K; Hofman MS; Hope TA; Horvath LG; Hussain MHA; Jereczek-Fossa BA; Jones RJ; Joshua AM; Kanesvaran R; Keizman D; Khauli RB; Kramer G; Loeb S; Mahal BA; Maluf FC; Mateo J; Matheson D; Matikainen MP; McDermott R; McKay RR; Mehra N; Merseburger AS; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Mutambirwa SBA; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Renard-Penna R; Ryan CJ; Saad F; Sade JP; Sandhu S; Sartor OA; Schaeffer E; Scher HI, 2025, 'Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)', in European Urology, pp. 157 - 216, http://dx.doi.org/10.1016/j.eururo.2024.09.017

Apostolov E; Roden DL; Holliday H; Cazet A; Harvey K; Zhang H; Wu SZ; van der Leij S; Selth LA; Bartonicek N; Al-Eryani G; He M; Lundeberg J; Reeves J; Kench JG; Potter AJ; Stricker P; Joshua AM; Horvath L; Swarbrick A, 2024, Profiling of epithelial functional states and fibroblast phenotypes in hormone therapy-naïve localised prostate cancer, http://dx.doi.org/10.1101/2024.10.23.619925

Azad A; Voskoboynik M; Joshua AM; Weickhardt AJ; Sankey P; Pacey S; Heath EI; Krieger L; Horvath L; Pilie PG; Womersley L; Linardopoulos S; Moorthy G; Zhou TJ; Brown J; de Paula B; Lukacs E; Hudson A, 2024, 'PETRANHA: Phase 1/2 study of AZD5305+novel hormonal agents in patients with metastatic prostate cancer-Interim safety and pharmacokinetic results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 42, pp. 123 - 123, presented at American-Society-of-Clinical-Oncology: Genitourinary Cancers Symposium (ASCO GU), CA, San Francisco, 25 January 2024 - 27 January 2024, http://dx.doi.org/10.1200/JCO.2024.42.4_suppl.123

Cai Z; Boys EL; Noor Z; Aref A; Xavier D; Lucas N; Williams SG; Koh JMS; Poulos RC; Wu Y; Dausmann M; MacKenzie KL; Aguilar-Mahecha A; Armengol C; Barranco MM; Basik M; Bowman ED; Clifton-Bligh RJ; Connolly EA; Cooper WA; Dalal B; DeFazio A; Filipits M; Flynn PJ; Graham JD; George J; Gill AJ; Gnant M; Habib R; Harris CC; Harvey K; Horvath LG; Jackson C; Kohonen-Corish MRJ; Lim E; Liu J; Long G; Lord RV; Mann GJ; McCaughan GW; Morgan L; Murphy LC; Nagabushan S; Nagrial AM; Navinés J; Panizza BJ; Samra JS; Scolyer RA; Souglakos I; Swarbrick A; Thomas DM; Balleine RL; Hains PG; Robinson PJ; Zhong Q; Reddel RR, 2024, Federated deep learning enables cancer subtyping by proteomics, http://dx.doi.org/10.1101/2024.10.16.618763

Horvath LG; Lin H-M; Davis ID; Martin A; Scheinberg T; Meikle P; Joshua A; Mcjannett M; Subhash V; Yip S; North S; McDermott RS; Chi KN; Stockler MR; Sweeney C, 2024, '1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)', in Annals of Oncology, Elsevier BV, Vol. 35, pp. S969 - S970, http://dx.doi.org/10.1016/j.annonc.2024.08.1688

Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Barnes EH; Goldstein D; Park SB, 2024, Peripheral Neuropathy in Cancer Patients- Multifactorial Contributors to Dose Limiting and Chronic Toxicity, http://dx.doi.org/10.1101/2024.07.24.24310956

Strach MC; Yeung N; Apostolov E; Wang T; Lin H-M; Ansari N; Koh C; Shin J-S; Kench J; Swarbrick A; Horvath L; Mahon KL, 2024, 'Abstract 5480: Single cell and spatial transcriptomic profile of appendiceal tumour peritoneal disease', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. 5480 - 5480, http://dx.doi.org/10.1158/1538-7445.am2024-5480

Fethney J; Kim B; Boustany C; McKenzie H; Hayes L; Cox K; Simpson JM; Horvath LG; Vardy JL; McLeod J; Willcock S; Cook N; Acret L; White K, 2023, Evaluating a shared care pathway intervention to reduce chemotherapy outpatients’ unplanned presentations to hospital: a randomised controlled trial, http://dx.doi.org/10.21203/rs.3.rs-3226857/v1

Horvath L; Lin H-M; Huynh K; Meikle T; Joshua AM; Azad A; Tan W; Butler L; Meikle P, 2023, 'Circulating ether lipids in prostate cancer', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Mellor R; Ardolino L; Scheinberg T; Sullivan D; Lin H-M; Meikle P; Stockler M; Joshua A; Horvath L, 2023, 'Evolocumab in Metastatic Castration-Resistant Prostate Cancer - study schema', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 68 - 68

Scheinberg T; Lin H-M; Fitzpatrick M; Azad A; Bonnitcha P; Davies A; Heller G; Huynh K; Mak B; Mahon K; Mellor R; Sullivan D; Meikle P; Horvath L, 2023, 'PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 84 - 84

Yeung N; Lin H-M; Timmins H; Li T; Goldstein D; Friedlander M; Harrison ML; Mahon KL; Meikle P; Park S; Horvath L, 2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Danila DC; Waterhouse DM; Appleman LJ; Pook DW; Matsubara N; Dorff TB; Lee J-L; Armstrong AJ; Kim M; Horvath L; Sumey CJ; Cooner F; Salvati M; Stieglmaier J; Kelly WK, 2022, 'A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS5101 - TPS5101, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps5101

Davis ID; Martin AJ; Zielinski RR; Thomson A; Tan TH; Sandhu S; Reaume MN; Pook DW; Parnis F; North SA; Marx GM; McCaffrey J; McDermott RS; Lawrence NJ; Horvath L; Frydenberg M; Chowdhury S; Chi KN; Stockler MR; Sweeney C, 2022, 'Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. LBA5004 - LBA5004, http://dx.doi.org/10.1200/jco.2022.40.17_suppl.lba5004

Edmunds K; Arora S; Roberts M; Fairbairn D; Scuffham P; Smith D; Chambers S; Horvath L; Tuffaha H, 2022, 'Genetic testing in prostate cancer: a scoping literature review', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 179 - 180, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000871956500285&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Fettke H; Hauser C; Kwan EM; Dai C; Zheng T; Wang A; Tan W; Du P; Ng N; Bukczynska P; Foroughi S; Graham L-JK; Horvath L; Mahon KL; Jia S; Kohli M; Azad A, 2022, 'Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at ASCO Genitourinary Cancers Symposium, ELECTR NETWORK, 17 February 2022 - 19 February 2022, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.153

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5027 - 5027, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5027

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of Lu-177-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301444&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Knox A; Fettke H; Hauser C; Bukczynska P; Ng N; Foroughi S; Graham L-JK; Mahon KL; Tan W; Zheng T; Dai C; Du P; Jia S; Horvath L; Kohli M; Azad A; Kwan EM; Wang A, 2022, 'Age-based assessment of cell-free DNA genomic profiles in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at ASCO Genitourinary Cancers Symposium, ELECTR NETWORK, 17 February 2022 - 19 February 2022, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.150

Mak B; Lin H-M; Mahon KL; Joshua AM; Stockler MR; Gurney H; Parnis F; Zhang AY; Scheinberg T; Wittert G; Butler L; Hoy A; Meikle P; Horvath L, 2022, 'Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.154

McBride SM; Niazi T; Williams S; Davis ID; Stockler MR; Martin AJ; Bracken K; Roncolato FT; Horvath L; Sengupta S; Martin J; Lim T; Hughes S; McDermott RS; Catto JWF; Kelly PJ; Parulekar WR; Morgan SC; Rendon RA; Sweeney C, 2022, 'DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at ASCO Genitourinary Cancers Symposium, ELECTR NETWORK, 17 February 2022 - 19 February 2022, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.TPS284

Niazi T; McBride SM; Williams S; Davis ID; Stockler MR; Martin AJ; Bracken K; Roncolato F; Horvath L; Sengupta S; Martin J; Lim T; Hughes S; McDermott RS; Catto JWF; Kelly PJ; Parulekar WR; Morgan SC; Rendon RA; Sweeney C, 2022, 'DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS5103 - TPS5103, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps5103

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Ravi Kumar A; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5017 - 5017, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5017

Scheinberg T; Fitzpatrick M; Lin H-M; Azad AA; Bonnitcha P; Davies AG; Heller G; Huynh K; Mak B; Mahon K; Meikle P; Sullivan D; Horvath LG, 2022, 'Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1189 - S1189, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000866211601666&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Smith MR; Agarwal N; Todenhofer T; Piulats JM; Lee J-L; Trepiakas R; Rao A; Horvath L; Lithio A; Johnston EL; Hulstijn M; Nacerddine K; Sweeney C, 2022, 'CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at ASCO Genitourinary Cancers Symposium, ELECTR NETWORK, 17 February 2022 - 19 February 2022, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.TPS198

Strach MC; Ansari N; Koh C; Solomon M; Horvath L; Mahon K, 2022, 'Outcomes of appendiceal cancer treated at a state peritonectomy service.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301169&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Strach MC; Ansari N; Koh C; Solomon M; Horvath L; Mahon K, 2022, 'Outcomes of appendiceal cancer treated at a state peritonectomy service.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3629 - 3629, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3629

Strach MC; Yeung N; Apostolov E; Lin H-M; Nagaraju RT; Ansari N; Koh C; Shin J-S; Kench J; Aziz O; Swarbrick A; Horvath LG; Barriuso J; Mahon K, 2022, 'Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1322 - S1322, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.1791

Strach MC; Yeung N; Lin H-M; Ansari N; Koh C; Shin J-S; Kench J; Centenera M; Butler L; Horvath L; Mahon K, 2022, 'Patient-derived explant model of appendiceal cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Strach MC; Yeung N; Lin H-M; Ansari N; Koh C; Shin J-S; Kench J; Centenera M; Butler L; Horvath L; Mahon K, 2022, 'Patient-derived explant model of appendiceal cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 4160 - 4160, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.4160

Tie J; Cohen J; Lahouel K; Lo SN; Wang Y; Wong R; Shapiro J; Harris S; Khattak A; Burge M; Horvath LG; Karapetis CS; Shannon J; Singh M; Yip D; Papadopoulos N; Tomasetti C; Kinzler K; Vogelstein B; Gibbs P, 2022, 'Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S683 - S683, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.456

Fizazi K; Mella PG; Castellano D; Minatta JN; Rezazadeh A; Shaffer DR; Vazquez Limon JC; Sanchez Lopez HM; Armstrong AJ; Horvath L; Dzik C; Amin NP; Li J; Unsal-Kacmaz K; Retz M; Saad F; Petrylak DP; Pachynski RK, 2021, 'CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at ASCO Genitourinary Cancers Symposium (GU ASCO), ELECTR NETWORK, 11 February 2021 - 13 February 2021, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.12

Hayes V; Jaratlerdsiri W; Jiang J; Gong T; Patrick S; Willet C; Chew T; Lyons R; Haynes A-M; Pasqualim G; Louw M; Kench J; Campbell R; Chan E; Wedge D; Sadsad R; Brum I; Mutambirwa S; Stricker P; Bornman R; Horvath L, 2021, African-specific prostate cancer molecular taxonomy, http://dx.doi.org/10.21203/rs.3.rs-1122619/v1

Kelly WK; Pook DW; Appleman LJ; Waterhouse DM; Horvath L; Edenfield WJ; Matsubara N; Danila DC; Aggarwal RR; Petrylak DP; Sartor OA; Sumey CJ; Adra N; Armstrong AJ; Cheng F-C; Stieglmaier J; Kouros-Mehr H; Dorff TB, 2021, 'Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at ASCO Genitourinary Cancers Symposium (GU ASCO), ELECTR NETWORK, 11 February 2021 - 13 February 2021, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS183

Kwan EM; Dai C; Fettke H; Hauser C; Bukczynska P; Ng N; Foroughi S; Graham L-JK; Mahon KL; Tan W; Wang A; Zhao Z; Zheng T; Zhou K; Yu J-J; Du P; Horvath L; Jia S; Kohli M; Azad A, 2021, 'Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at ASCO Genitourinary Cancers Symposium (GU ASCO), ELECTR NETWORK, 11 February 2021 - 13 February 2021, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.159

Lin H-M; Mak B; Huynh K; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Stockler MR; Briscoe K; Marx GM; Du P; Yu J; Jia S; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG, 2021, 'Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S666 - S667, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1148

Mak B; Lin H-M; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Stockler MR; Briscoe K; Marx GM; Kohli M; Tan W; Huynh K; Du P; Yu J; Jia S; Joshua AM; Azad AA; Meikle PJ; Horvath LG, 2021, 'Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S642 - S643, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1109

Niazi T; Williams S; Davis ID; Stockler MR; Martin AJ; Bracken K; Roncolato F; Horvath L; Martin J; Lim TS; Hughes S; McDermott RS; Catto JWF; Kelly PJ; McBride SM; Parulekar WR; Morgan SC; Rendon RA; Sweeney C, 2021, 'DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at ASCO Genitourinary Cancers Symposium (GU ASCO), ELECTR NETWORK, 11 February 2021 - 13 February 2021, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS266

Sandhu SK; Joshua AM; Emmett L; Spain L; Horvath LG; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Kumar AR; Alipour R; Akhurst T; Kong G; Davis ID; Williams S; Hicks R; Hofman M, 2021, 'PRINCE: Interim analysis of the phase Ib study of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S626 - S627, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1090

2021, 'A psychometric comparison of three approaches to chemotherapy-induced peripheral neuropathy assessment: Patient report, clinical grading, and sensory function', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. S96 - S96, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000712224700205&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ben T; Horvath L; Rettig M; Fizazi K; Lolkema MP; Dorff TB; Greil R; Machiels J-PH; Autio KA; Rottey S; Adra N; Garje R; Roncolato F; Tagawa ST; Shariat SF; Salvati M; Poon S; Kouros-Mehr H, 2020, 'Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020

Butler LM; Mah CY; Dehairs J; Vincent A; Mutuku S; Spotbeen X; Das R; Nassar Z; Selth L; Trim P; Snel M; Lynn D; Horvath L; Tilley W; Centenera M; Swinnen J, 2020, 'Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-2076

Dorff T; Rettig M; Machiels J-P; Lolkema M; Autio K; Greil R; Rottey S; Adra N; Salvati M; Poon S; Tan D; Jurida G; Kouros-Mehr H; Fizazi K; Tran B; Horvath L, 2020, 'PHASE 1 STUDY OF AMG 160, A HALF-LIFE EXTENDED BITE (R) (BISPECIFIC T-CELL ENGAGER) THERAPY TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A207 - A208, http://dx.doi.org/10.1136/jitc-2020-SITC2020.0340

Horvath LG; Lin H-M; Mak B; Mahon K; Yeung N; Docanto M; Sutherland P; Shepherd A; Tan W; Azad A; Kohli M; Meikle P; Butler L, 2020, 'Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 80, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-4761

Kelly WK; Danila DC; Edenfield WJ; Aggarwal RR; Petrylak DP; Sartor AO; Sumey CJ; Dorff TB; Yu EY; Adra N; Waterhouse DM; Armstrong AJ; Horvath L; Pook DW; Appleman LJ; Lau A; Salvati M; Kouros-Mehr H, 2020, 'Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020

Kelly WK; Danila DC; Edenfield WJ; Aggarwal RR; Petrylak DP; Sartor AO; Sumey CJ; Dorff TB; Yu EY; Adra N; Waterhouse DM; Armstrong AJ; Horvath L; Pook DW; Appleman LJ; Lau A; Salvati M; Kouros-Mehr H, 2020, 'Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. TPS5589 - TPS5589, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps5589

Kwan EM; Fettke H; Bukczynska P; Ng N; Hauser C; Graham L-JK; Mahon KL; Dai C; Xie F; Wang X; Zhao Z; Zhou K; Du P; Yu J; Jia S; Tan W; Horvath L; Kohli M; Azad A, 2020, 'Plasma cell-free DNA (cfDNA) profiling of copy number variation (CNV) to identify poor prognostic biomarkers in metastatic castration-resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 38, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900245&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kwan EM; Fettke H; Bukczynska P; Ng N; Hauser C; Graham L-JK; Mahon KL; Dai C; Xie F; Wang X; Zhao Z; Zhou K; Du P; Yu J; Jia S; Tan W; Horvath L; Kohli M; Azad A, 2020, 'Plasma cell-free DNA (cfDNA) profiling of copy number variation (CNV) to identify poor prognostic biomarkers in metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. 176 - 176, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.176

Li T; Timmins H; McCrary J; Trinh T; Friedlander M; Horvath L; Kiernan M; Goldstein D; Park S, 2020, 'Patient reported outcome scores used in chemotherapy-induced peripheral neuropathy: Defining minimal important differences', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, ELECTR NETWORK, Vol. 25, pp. 481 - 481, presented at Virtual Conference of Peripheral-Nerve-Society, ELECTR NETWORK

Price TJ; Burge M; Chantrill L; Chua YJ; Horvath L; McLachlan S-A; Pavlakis N; Shapiro J; Thavaneswaran S; Tran B; Yip D; Tancock G, 2020, 'Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1283 - S1283, presented at ESMO Asia Virtual Congress, ELECTR NETWORK, 20 November 2020 - 22 November 2020, http://dx.doi.org/10.1016/j.annonc.2020.10.127

Scheinberg T; Goodwin A; Ip E; Linton A; Mak B; Smith DP; Stockler M; Strach M; Tran B; Young AL; Zhang A; Mahon K; Horvath L, 2020, 'Evaluation of a mainstream model of genetic testing for men with prostate cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 16, pp. 40 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000594482700020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sengupta S; Niazi T; Williams S; Davis ID; Stockler M; Martin AJ; Bracken K; Roncolato FT; McJannett M; Horvath L; Hughes S; Mc Dermott R; Catto J; Kelly P; Parulekar W; Morgan S; Rendon R; Sweeney CJ, 2020, 'DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 204 - 204

Stradella A; Johnson M; Goel S; Chandana SR; Galsky MD; Calvo E; Moreno V; Park H; Arkenau T; Cervantes A; Farinas-Madrid L; Mileshkin L; Fu S; Plummer R; Evans J; Horvath L; Prawira A; Qu K; Pelham R; Barve MA, 2020, 'Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S465 - S466, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.644

Tran B; Horvath L; Dorff T; Rettig M; Lolkema MP; Machiels J-P; Rottey S; Autio K; Greil R; Adra N; Lemech C; Minocha M; Cheng F-C; Kouros-Mehr H; Fizazi K, 2020, 'Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE (R)) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S507 - S507, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.869

Tran B; Horvath L; Dorff TB; Greil R; Machiels J-PH; Roncolato F; Autio KA; Rettig M; Fizazi K; Lolkema MP; Fermin AC; Salvati M; Kouros-Mehr H, 2020, 'Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tran B; Horvath L; Rettig M; Fizazi K; Lolkema MP; Dorff TB; Greil R; Machiels J-PH; Autio KA; Rottey S; Adra N; Garje R; Roncolato F; Tagawa ST; Shariat SF; Salvati M; Poon S; Kouros-Mehr H, 2020, 'Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. TPS5590 - TPS5590, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps5590

Voskoboynik M; Richardson GE; Mileshkin LR; McNeil CM; Horvath L; Benedetti FM; Choy GS; Sankar N; McCurry S; Zhang X; Gao M; Shah AK; Millward M, 2020, 'A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368305113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2020, 'DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S548 - S549, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.2088

Desai J; Markman B; Friedlander M; Gan H; Horvath L; Townsend A; Millward M; Jameson M; Yen C-J; Hou M-M; Hou J; Wu J; Liang L; Deva S, 2019, 'Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in Clinical Trials, American Association for Cancer Research, pp. CT084 - CT084, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-ct084

Desai J; Markman B; Friedlander M; Gan H; Horvath L; Townsend A; Millward M; Jameson M; Yen C-J; Hou M-M; Hou J; Wu J; Liang L; Deva S, 2019, 'Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-CT084

Mahon KL; Lin H-M; Lee-Ng M; Stockler MR; Gurney H; Mallesara G; Briscoe KP; Marx GM; Higano CS; De Bono JS; Chi KN; Brown D; Breit SN; Horvath L, 2019, 'Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.230

Mak B; Mahon KL; Stockler MR; Joshua AM; Zhang AY; Parnis F; Meikle P; Horvath L, 2019, 'Modulation of plasma lipidomic signature in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.TPS331

Millward M; Gan HK; Joshua AM; Kuo JC-Y; Prawira A; Richardson GE; Barbee SD; Inamdar SP; Pierce KL; Qureshi M; Horvath L, 2019, 'FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.8_suppl.TPS42

Nassar ZD; Mah CY; Dehairs J; Burvenich IJG; Irani S; Centenera MM; Shrestha RK; Moldovan M; Don AS; Scott AM; Horvath LG; Lynn DJ; Selth LA; Hoy AJ; Swinnen JV; Butler LM, 2019, DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis, http://dx.doi.org/10.1101/865626

Powderly JD; de Souza PL; Gutierrez R; Horvath L; Seitz L; Ashok D; Park A; Walters MJ; Karakunnel JJ; Berry W; Rieger A; Garofalo A; Lai DW; Chaudhry A, 2019, 'AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2604

Stradella A; Johnson ML; Goel S; Chandana SR; Galsky MD; Calvo E; Moreno V; Park H; Arkenau H-T; Cervantes A; Farinas Madrid L; Mileshkin L; Plummer R; Evans J; Horvath L; Prawira A; Pelham RJ; Mu S; Andreu-Vieyra C; Barve M, 2019, 'Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (Id) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, pp. 166 - +, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295501268&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tran B; Kouros-Mehr H; Fermin A; Horvath L; Roncolato F; Rettig M; Dorff T; Tagawa ST; Subudhi SK; Antonarakis ES; Armstrong AJ; Petrylak DP; Fizazi K; Salvati ME; Scher HI, 2019, 'A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 353 - 353, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295502322&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, 'A phase 1 study of FPT155, a first-in-class CD80 extracellular domain-Fc fusion protein, in patients with advanced solid tumors', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMC, Vol. 7, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000496473200862&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, 'Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, pp. 886 - +, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295500177&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, 'Novel Targets for an In Vivo DC Anti-Prostate Cancer Vaccine', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 64 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, 'Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (Ribociclib) in High-Risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (Leep Study)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 64 - 64, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200064&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, 'Phase 3 Study of Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) or Placebo (PBO) in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): The Arches Trial', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 32 - 33, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kwan EM; To S; Fettke H; Mant AM; Docanto M; Martelotto L; Bukczynska P; Ng N; Graham L-J; Parente P; Pezaro CJ; Mahon KL; Horvath L; Todenhofer T; Azad A, 2018, 'Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 36, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.252

Kwan EM; To SQ; Fettke HC; Mant AM; Docanto MM; Bukczynska P; Ng N; Graham L-JK; Parente P; Pezaro CJ; Mahon KL; Horvath L; Todenhofer T; Azad A, 2018, 'Correlating whole blood AR-V7 and AR-V9 with therapy response to AR-targeted therapies in metastatic castrate-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e17070

Mahon KL; Stricker P; Kench J; Grogan J; Delprado W; Turner J; Horvath L; Quinn DI, 2018, 'P53 as a predictor of clinical outcome in localized prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 36, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.57

Price TJ; Falcone A; Chantrill L; Horvath L; Chua YJ; Burge M; McLachlan S-A; Van Hazel G; Pavlakis N; Shapiro J; Taieb J; Seitz JF; Wyrwicz L; Becquart M; Moreno S; Mounedji N; Van Cutsem E, 2018, 'Baseline Patient Characteristics in the International, Open-Label, Preconnect Study of Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer (PHASE-IIIB)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 71 - 72, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100050&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Zhang AY; Chiam K; Haupt Y; Fox SB; Birch S; Tilley W; Butler L; Knudsen KE; Cornstock C; Rasiah K; Grogan J; Mahon KL; Bianco-Miotto T; Bohm M; Henshall SM; Delprado W; Stricker P; Horvath L; Kench J, 2018, 'An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 36, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.54

2018, 'P53 as a Predictor of Clinical Outcome in Localised Prostate Cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 65 - 66, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2018, 'Post Hoc Analysis of a Phase III Study to Test the Association Between Circulating Methylated Glutathione S Transferase (mGSTP1) DNA Levels and Response to Docetaxel (DTX) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 51 - 52, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2018, 'The Clinical Impact of Treating Localised Prostate Cancer - The Australian Experience', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 47 - 47, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000437670700052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Desai J; Gan H; Barrow C; Jameson MB; Solomon B; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Gibbs D; Parente P; Yang J; Wang L; Chen Y; Luo L, 2017, 'A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-CT002

Meniawy T; Richardson G; Townsend A; Desai J; Gan H; Friedlander M; Horvath L; Jameson MB; Sandhu S; Wu Z; Qin Z; Kang K; Markman B, 2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324001049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Timmins HC; Li T; Kiernan MC; Horvath LG; Harrison M; Grimison P; Cox KM; Boyle FM; Goldstein D; Park SB, 2017, 'NEUROPHYSIOLOGICAL MEASURES CORRELATE WITH PATIENT REPORTED SYMPTOMS OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, SPAIN, Sitges, Vol. 22, pp. 395 - 396, presented at Peripheral-Nerve-Society Meeting, SPAIN, Sitges, 08 July 2017 - 12 July 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000409243500424&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

To S; Kwan E; Fettke H; Docanto M; Ng N; Mant A; Parente P; Pezaro C; Horvath L; Graham L; Todenhofer T; Azad A, 2017, 'Whole blood assay for rapid detection of AR-v7 in metastatic castration-resistant prostate cancer: No correlation with response to androgen-axis targeting agents.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, FL, Orlando, pp. 78 - 78, presented at AACR Special Conference on Prostate Cancer - Advances in Basic, Translational, and Clinical Research, FL, Orlando, 02 December 2017 - 05 December 2017, http://dx.doi.org/10.1158/1538-7445.PRCA2017-A098

Zhang A; Grogan J; Mahon K; Rasiah K; Sved P; Eisinger D; Boulas J; Vasilaris A; Henshall S; Stricker P; Kench J; Horvath L, 2017, 'A PROSPECTIVE MULTI-CENTER PHASE III VALIDATION STUDY OF AZGP1 AS A BIOMARKER IN LOCALISED PROSTATE CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 64 - 64, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427541700115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler M; Briscoe K; Marx G; Horvath LG, 2016, 'Validation of circulating microRNA biomarkers of docetaxel outcome in castration-resistant prostate cancer', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Melbourne, Vol. 118, pp. 22 - 22, presented at 17th Asia-Pacific Prostate Cancer Conference, AUSTRALIA, Melbourne, 31 August 2016 - 03 September 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000381708200046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahon K; Lin H-M; Spielman C; Lee-Ng M; Gurney H; Mallesara G; Stockler M; Briscoe K; Marx G; Breit SN; Brown D; Horvath L, 2016, 'PHASE II TRIAL OF CIRCULATING CYTOKINES AS MARKERS OF DOCETAXEL RESISTANCE IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (mCRPC)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 12, pp. 37 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380004900039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahon K; Lin HM; Spielman C; Lee-Ng M; Gurney H; Mallesara G; Stockler M; Briscoe K; Marx G; Breit SN; Brown DA; Horvath LG, 2016, 'Phase II trial of circulating cytokines as markers of docetaxel resistance in metastatic castrateresistant prostate cancer (mCRPC)', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Melbourne, Vol. 118, pp. 21 - 21, presented at 17th Asia-Pacific Prostate Cancer Conference, AUSTRALIA, Melbourne, 31 August 2016 - 03 September 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000381708200045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler M; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark S; Swarbrick A; Daly R; Horvath L, 2014, 'CIRCULATING MICRORNAS ASSOCIATED WITH DOCETAXEL-RESISTANT CASTRATION-RESISTANT PROSTATE CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 26 - 27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716200012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahon KL; Qu W; Devaney J; Paul C; Castillo L; Wykes R; Chatfield MD; Boyer MJ; Stockler MR; Marx GM; Gurney H; Gowda GMH; Molloy P; Horvath L; Clark SJ, 2014, 'Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.11

Nagrial A; Chin V; Steinmann A; Chou A; Grimmond S; Horvath L; Pajic M; Biankin A, 2014, 'GENOMIC CLASSIFIER FOR PANCREATIC DUCTAL ADENOCARCINOMA THERAPEUTIC RESPONSE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 44 - 44, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Zhang AY; Butler LM; Stricker PD; Kench JG; Tilley WD; Sebastian L; Stockler M; Horvath L, 2014, 'PHARMACODYNAMIC EFFECTS OF THE HEAT SHOCK PROTEIN 90 (HSP90) INHIBITOR, AUY922, IN HIGH-RISK, LOCALISED PROSTATE CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 46 - 46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716200068&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Horvath L; Chatfield MD; Lee-Ng M; Lin H-M; Castillo L; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockier MR; Wykes R; Henshall SM; Mahon KL, 2013, 'The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419605294&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahon K; Chatfield M; Breit S; Brown D; Molloy M; Marx G; Pavlakis N; Boyer M; Stockler M; Horvath L, 2013, 'The role of macrophages in Docetaxel (DTX) resistance in castrate resistant prostate cancer (CRPC)', in BJU INTERNATIONAL, WILEY-BLACKWELL, pp. 30 - 31, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000321969100078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Cooper WA; Yu B; Yip PY; Farzin M; Clarkson A; Kohonen-Corish MJ; Horvath L; Kench JG; McCaughan B; O'Toole SA; Gill AJ, 2012, 'EGFR MUTANT SPECIFIC IMMUNOHISTOCHEMISTRY HAS HIGH SPECIFICITY BUT ONLY MODERATE SENSITIVITY FOR DETECTING COMMON ACTIVATING EGFR MUTATIONS IN LUNG ADENOCARCINOMA', in JOURNAL OF THORACIC ONCOLOGY, ELSEVIER SCIENCE INC, AUSTRALIA, Adelaide, Vol. 7, pp. S162 - S162, presented at 4th Australian Lung Cancer Conference, AUSTRALIA, Adelaide, 23 August 2012 - 25 August 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000317034900018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lee BY; Hochgraefe F; Lin HM; Castillo L; Raftery M; Horvath LG; Daly RJ, 2012, 'Overcoming Docetaxel Resistance in Prostate Cancer by Targeting FAK Phosphorylation, and Its Mode of Action', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, pp. 48 - 49, presented at 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, 06 November 2012 - 09 November 2012, http://dx.doi.org/10.1016/S0959-8049(12)71956-1

Yip PY; Yu B; Cooper WA; Kench JG; Boyer M; Kohonen-Corish MJ; Trent R; McCaughan B; Kennedy C; O'Toole SA; Horvath L, 2012, 'MUTATIONS IN RESECTED NODE-NEGATIVE LUNG ADENOCARCINOMA', in JOURNAL OF THORACIC ONCOLOGY, ELSEVIER SCIENCE INC, AUSTRALIA, Adelaide, Vol. 7, pp. S189 - S190, presented at 4th Australian Lung Cancer Conference, AUSTRALIA, Adelaide, 23 August 2012 - 25 August 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000317034900113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Moore MM; Chua W; Zhao J; Clarke SJ; Horvath L, 2009, 'Evaluation of plasma total and cleaved cytokeratin 18 as predictive markers of chemotherapy in colorectal cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276606601162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Thanigasalam R; Rasiah K; Stricker P; Earnest A; Haynes AM; Sutherland S; Sutherland RL; Henshall S; Horvath L, 2008, 'Analysis of stage migration in localised prostate cancer in Australia and its impact on the post radical prostatectomy Kattan nomogram', in British Journal of Urology, WILEY-BLACKWELL, Hong Kong, PEOPLES R CHINA, pp. 35 - 35, presented at British Journal of Urology, Hong Kong, PEOPLES R CHINA, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000252815500114&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a